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Salmonella Typhimurium is a Gram-negative bacterial pathogen and a common cause of 
gastroenteritis in humans.  The organism utilizes a multitude of well-studied virulence 
factors to invade and replicate in host intestinal epithelial cells and macrophages.  
Interestingly, Salmonella is also capable of localizing to tumors in in vivo model systems, 
and while the typical route of Salmonella infection and pathogenesis has been thoroughly 
investigated, the behavior of Salmonella in the tumor microenvironment has not.  
Therefore, to investigate Salmonella and host behavior during bacterial-neoplastic cell 
interactions, I utilized two high-throughput screens.  In the first, I designed a 
bioluminescent transposon-reporter trap to identify specific Salmonella genes activated in 
the context of cancer cell co-culture conditions.  Through this work, I identified five 
Salmonella genes reproducibly activated by co-culture with cancer cells, and further 
isolated the activating stimulus to low pH.  Because low pH is a common characteristic of 
the tumor microenvironment, I also demonstrated the pH inducibility and reversibility of 
Salmonella gene activation in tumors ex vivo and in vivo.  In a separate study, to better 
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understand how host neoplastic cells respond to Salmonella, I investigated the ability of 
Salmonella to induce pro-inflammatory responses in HCT116 colon carcinoma cells, 
specifically, NF-κB activation. Then, I performed a high-throughput siRNA screen to 
identify novel host kinases and phosphatases involved in detection of Salmonella and 
activation of NF-κB signaling.  For this work, I used a reporter construct consisting of an 
IκBα-firefly luciferase fusion protein transcriptionally activated by NF-κB.  The reporter 
permitted imaging of both degradation of the NF-κB negative inhibitor IκBα and its 
resynthesis, which is dependent on NF-κB activation, following stimulus with 
Salmonella. The host kinase, NME3, was identified in the screen as a specific modulator 
of NF-κB.  Knockdown of NME3 prevents proper activation of NF-κB signaling 
pathways in HCT116 cells exposed to Salmonella, demonstrating the role of this kinase 
as a positive regulator of NF-κB pro-inflammatory signaling in colon carcinoma cells.   
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CHAPTER 1 
Introduction 
1.1 Introduction to Salmonella 
The genus Salmonella represents a large and diverse collection of Gram-negative bacteria 
belonging to the family Enterobacteriaceae [1].  It consists of two species of facultatively 
anaerobic bacilli, S enterica and S bongori [1]. Six subspecies exist within the species 
Salmonella enterica of which one, Salmonella enterica enterica, accounts for 59% of all 
Salmonella isolates, are the only strains regularly found in warm-blooded animals, and 
include 99% of disease-associated isolates [1].  This subspecies is further divided into 
multiple serovars based on antigenic determinants of the bacterium, such as its flagellin 
protein and outer polysaccharide structure [1].  Salmonella enterica enterica includes the 
pathogenic serovars Salmonella Typhimurium, Salmonella Enteritidis and Salmonella 
Typhi [1].   
In the environment, Salmonella are maintained as normal flora in multiple diverse 
vertebrate animals including chickens, cattle and reptiles [2].  Perhaps due to its ubiquity 
in the environment, Salmonella is one of the leading causes of food poisoning in the 
United States each year [3].  The organism typically causes 30,000-40,000 confirmed 
infections in the United States annually, approximately 400 of which are fatal, although 
the true number of Salmonella infections is likely much higher [3].  When transmitted to 
humans, typically by contaminated food and water, Salmonella cause an infection termed 
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Salmonellosis, which most commonly results in a self-limiting gastroenteritis [4].  S. 
Typhimurium is also capable of more severe sequelae and can cause endocardidits and 
vascular infections by adhering to endothelial cells.  In the most severe cases, Salmonella 
can progress to a systemic bacteremia in infected hosts by replicating and surviving 
within macrophages.    
 
1.2 The Pathogenesis of Salmonella Typhimurium 
Invasion 
The pathogenesis of Salmonella Typhimurium has been studied in detail and much is 
known about its virulence factors and the molecular mechanisms used during infection of 
its host (Figure 1-1).  During the typical route of infection, Salmonella bacteria travel 
through the stomach to the intestine following ingestion [4].  Once in the intestinal 
lumen, the bacteria utilize type 1 fimbrae to attach to enterocytes [5].  Local 
environmental conditions in the distal small intestine, the preferred site of Salmonella 
invasion, induce bacteria to activate the Salmonella pathogenicity island 1 (SPI-1) genes 
[6, 7].  SPI-1 refers to one of multiple clusters of virulence genes in the Salmonella 
genome and encodes multiple important virulence genes, including those encoding a type 
three secretion system (TTSS) and effector proteins that target the host cell [8-14].  The 
SPI-1 TTSS is a needle-like apparatus with structural similarity to bacterial flagellin [15, 
16].  It consists of a basal body, anchoring the structure to the bacterial cell membrane, an 
ATPase motor and a translocon made of repeating filament protein, capable of delivering 
effector proteins directly from the bacterial cytosol into the eukaryotic cell [15, 16].  The 
SPI-1 TTSS has been shown to translocate at least 13 proteins [14]. Many of the secreted 
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effectors are involved in modulating host actin to induce Salmonella uptake into the host 
cell, indicating an essential role for the SPI1 in bacterial invasion [14].  One of these 
effectors, SipC, has two important functions.  SipC acts both as an outer structural 
component of the TTSS translocon by forming a pore in the target cell membrane, as well 
as a nucleator of host actin filaments [17, 18].  As the first secreted effector, SipC 
therefore begins the host cytoskeletal filamentation process.  The second secreted effector 
protein, SipA, promotes and enhances the actin filamentation process set into motion by 
SipC [19].  In addition to the initial actin filamentation steps induced by SipC and SipA, 
Salmonella utilizes additional effectors to further induce branching of actin filaments, 
which fuels the host cell membrane ruffling that promotes bacterial uptake.  Two of these 
effectors, SopE and SopE2, act as guanine exchange factors (GEFs) for host Rac and 
Cdc42 GTPase proteins [20-22]. The GEF activity of SopE and SopE2 enhances the 
activity of these host cell molecular switch GTPases, which induce actin branching and 
cytoskeleton assembly [20-22].  The cooperative actions of SipC and SipA with SopE 
and SopE2 cause drastic host actin filamentation that results in full uptake of the bacteria 
into a Salmonella Containing Vacuole (SCV) within the host intracellular space.   
Following bacterial entry, Salmonella effector proteins are also responsible for restoring 
the host cell actin cytoskeleton to its normal architecture. SptP acts as a GTPase-
activating protein (GAP), and reverses the action of SopE by inactivating the host 
GTPases Rho and Cdc42 [23].  By taking advantage of the different stabilities of the 
SopE and SptP proteins, Salmonella can cover their tracks and reduce the possibility of 
alerting the immune system of their presence in the newly infected host cell[24].  SopE, 
as mentioned previously, is a GEF, promoting actin filamentation in target cells. While 
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SopE and SptP are injected by the SPI-1 TTSS in similar amounts, SopE is quickly 
targeted and degraded by the host proteasome [24].  Meanwhile, SptP persists to return 
the host cell membranes to their normal architecture [24].   
Intracellular Survival 
When Salmonella reach the intracellular compartment during infection, they utilize an 
additional set of effectors to modulate host cell trafficking and preserve the SCV.   
Within the host cell cytosol, Salmonella employ diverse mechanisms to control the 
composition, environment and intracellular location of the SCV.  In general, Salmonella 
within intestinal epithelial cells and those engulfed by infiltrating macrophages during an 
intestinal infection respond similarly, by modulating intracellular trafficking and 
replicating within their host cell [25].    Immediately after bacterial entry, the SCV is 
enriched in early endosome membrane markers [26].  Later, the SCV gains late 
endosomal and lysosomal markers, localizes to a juxtanuclear position, and acidifies [27, 
28].  Acidification of the SCV promotes activation of virulence genes and a second TTSS 
encoded by the SPI-2 pathogenicity island, while simultaneously repressing the 
previously used invasion genes of SPI-1 [29, 30].  SPI-2 virulence factors have been 
implicated in Salmonella modulation of host intracellular trafficking and signaling 
pathways as well as bacterial replication. SPI-2 knockouts are capable of invading host 
cells, but cause a much less severe disease in vivo, showing that these activities are 
required for a productive systemic infection [31].  It is unclear exactly how Salmonella 
modulate host cell trafficking while in the SCV, but, like the invasion process, the host 
cytoskeletal membrane dynamics are largely involved.  Sixteen effectors have been 
identified as secreted products of the SPI-2 TTSS and at least half of these have been 
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known to associate with the endosomal membrane system [32].  Within four to six hours 
of bacterial invasion of host cells, Sif (Salmonella induced filament) formation is 
observed [33, 34].  These membrane extensions of the SCV are enriched in lysosomal 
proteins and may form along microtubules [33, 34].  While Sif formation and function are 
not fully understood, Salmonella dedicates multiple effector proteins (SseF, SseG, SseJ 
and SifA) to their maintenance and robustly induces their formation in vitro, indicating 
their relevance to bacterial virulence and intracellular replication.   
1.3 Host Immunity to Salmonella 
The Innate Immune Response to Salmonella 
To detect and control Salmonella infection, hosts rely on the rapid response of innate 
immunity mechanisms.  Innate immunity is considered the first line of defense against a 
pathogenic organism such as Salmonella and consists of extracellular secreted defense 
molecules, host cell receptors and intracellular signaling pathways.  Human cells display 
multiple receptors designed to recognize pathogen associated molecular patterns 
(PAMPs) and alert the host as to the presence of a foreign organism.  PAMPs include 
bacterial lipospolyssacharide (LPS), peptidoglycan and flagellin.  PAMP receptors are 
referred to as pattern recognition receptors (PRRs) and those expressed in humans 
include Toll-like receptors (TLRs) and nucleotide oligomerization domain receptors 
(NODs).  Binding of a PAMP to one of these receptors causes activation of multiple host 
cell signaling pathways responsible for inducing inflammation, recruiting immune cells 
and releasing cytokines.   
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Toll-Like Receptors 
One of the major PRRs in the innate immunity system is the Toll-like receptor.  The first 
Toll receptor was discovered in Drosophila as a necessary player in proper development, 
but was later linked to immunity when Toll mutant flies were shown to be more 
susceptible to fungal infection.   To date, 10 different TLRs have been identified in 
mammalian cells (1-9 pictured in Figure 1-2) [35].  TLRs are type 1 transmembrane 
proteins consisting of an N-terminal extracellular (or intra-endosomal) region of leucine-
rich repeats involved in recognizing PAMPs and a cytoplasmic domain necessary for 
downstream signal transduction [35].   The cytoplasmic domain of TLRs closely 
resembles the IL-1 receptor cytoplasmic domain, and therefore both of these are called 
TIR or Toll/interleukin receptor domains [36].  All TLRs are similar in their structures 
and respond to foreign antigens.  However, TLRs are diverse in ligand specificity, 
subcellular location, required adapter proteins and induction of downstream signaling 
pathways.   TLR3, TLR7, TLR8, and TLR9 respond to intracellular stimuli and are 
located on endosomal membranes [35].  TLR3 is activated by double-stranded RNA 
while TLR7 and TLR8 have been shown to respond to single-stranded RNA, both of 
which are formed during a viral infection.  TLR7 and TLR8 have also been demonstrated 
to respond to synthetic imidazoquinolines, which are small antiviral compounds [37].   
TLR9 reacts to viral and bacterial CpG DNA.  The remaining TLRs: TLR2, TLR1, 
TLR6, TLR4 and TLR5 are typically found on the cell membrane and bind extracellular 
stimuli [35].  TLR2 alone recognizes peptidoglycan, but it also may heterodimerize with 
TLR1 or TLR6 to respond to bacterial lipopeptides.  TLR4 and TLR5 are activated by 
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bacterial lipopolysaccharide(LPS) and flagellin, respectively.  TLR10 has been 
discovered recently, and its specific ligand is not yet known [38].   
Once a TLR is activated, the timing of signal transmission and downstream effects are 
dependent on adapter proteins recruited to the cytoplasmic TIR domain of the TLR. In 
general, TLRs can be described as either MyD88-dependent or MyD88–independent 
based on the TIR-domain adapters utilized.  All TLRs except TLR3 and TLR4 require 
MyD88, though TLR4 can signal through a MyD88-dependent or MyD88-independent 
pathway [39, 40].  Some TLRs signal directly to MyD88, but TLR1, TLR2, TLR4 and 
TLR6 use a bridge adapter protein called TIRAP [40].  Once activated, MyD88 first 
recruits IRAK4 (IL-1R associated kinase), which in turn recruits IRAK1 and TRAF6 [41, 
42].  This leads to recruitment and activation of the TAK1/TAB kinase complex [43, 44].  
The TAK1/TAB kinase complex activates downstream targets including both MAPK 
(mitogen-activated protein kinase) pathways and the NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) pathway through IKK (inhibitor of κB kinase) [44]. 
In the case of TLR3 and TLR4, which can signal independently of the MyD88 adapter, 
TRIF binds directly to the TIR domain of TLR3 to transduce the signal, or TRAM serves 
as an adapter to TRIF in the case of TLR4 [40, 45]. TRIF activates TRAF6 and RIP1, 
leading to IKK activation, and downstream NF-κB signaling as in MyD88-dependent 
TLR activation, but on a much different timescale than MyD88 dependent TLR signaling 
[42, 46].  In addition to NF-κB, IRF3 (interferon regulator factor 3) is a key transcription 
factor activated in the MyD88-independent pathway [47].  In this signaling node, TLR3 
and TLR4 are both capable of activating non-canonical IKKs through TRAF3 [48].  The 
non-canonical IKKs (TBK1 and Ikke/IKKi) activate IRF3, which can then dimerize and 
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translocate to the nucleus, where it activates transcription at IFN-stimulated response 
elements (ISRE) [48].  IRF3 has also been shown to form a complex with NF-κB and 
ATF2/C-Jun called the enhanceasome, which activates interferon beta transcription [48].  
Although different TLRs have similar structures, diversity in response is achieved by the 
intracellular adapters and signaling proteins targeted by each TLR. 
Toll-Like Receptor 5   
Toll-like receptor 5 was discovered in 1998 and in 2001 was shown to recognize both 
Gram-positive and Gram-negative bacterial flagellin, and to robustly induce IL-6 
production in vivo in a MyD88-dependent manner [49].  TLR5 engagement leads to 
MAPK and NF-κB activation and the eventual downstream activation of 500 genes 
including chemokines, stress response genes and anti-apoptotic genes [50].  The receptor 
is expressed on dendritic cells, monocytes and epithelial cells, and is likely involved not 
only in classic response to pathogens, but also in keeping proper gut homeostasis [51, 
52]. 
TLR5 binds most bacterial flagellin.  In the Salmonella FliC protein, the specific 
recognition site has been isolated to a 13 amino acid sequence [53]. This sequence is 
required for flagellin filament polymerization and therefore bacterial motility, 
demonstrating the precision of the host innate immunity response [53].  Further, previous 
studies have demonstrated that flagellin is the major proinflammatory determinant of 
Salmonella in some cases and that flagellin exposure elicits a strong activation of 
cytokine release by host cells [50].    
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TLR5 activity is robustly pro-inflammatory, and therefore multiple mechanisms exist to 
keep activity in check.  The cell is capable of down-regulating TLR5 signaling thru PI3K 
(phosphoinositide 3-kinase), which prevents over-expression of proinflammatory genes 
by regulating MAPK signaling [54].  There is also evidence that the host protein Muc1 
can interact with flagellin and dampen downstream TLR5 signaling [55].  The location of 
TLR5 also contributes to its control. In vivo, TLR5 expression is limited to the basolateral 
membrane of the colon, thereby preventing overactive signaling due to flagellated 
commensal microbes in the intestinal lumen [56].  Flagellin must therefore breach the 
gastrointestinal barrier to induce signaling in normal cells.  Still, TLR5 is readily able to 
be activated by flagellin of commensals as well as pathogens, indicating that the 
accessibility of flagellin, and not the pathogenicity of the species, is the main factor in 
TLR5 activation [57].   
As an integral activator of inflammatory signaling, TLR5 loss or dysfunction has very 
serious consequences in the host.  A TLR5-deficient mouse model has been developed 
that fails to activate any proinflammatory pathways in response to flagellin, providing a 
valuable and informative system to study the importance of TLR5 in vivo.  The mice 
develop a severe metabolic syndrome marked by obesity and insulin resistance in 
addition to a tendency to develop spontaneous colitis [58, 59]. These phenotypes may be 
a result of changes in the composition of the microbiota, identifying a role for TLR5 in 
maintenance of proper gut homeostasis [58, 59].   
TLR5 loss has differing effects on Salmonella pathogenesis, depending on the route of 
infection.  TLR5 knockout mice develop more severe gastroenteritis in an antibiotic 
pretreatment mouse model of Salmonella intestinal infection [60].  However, the mice are 
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resistant to Salmonella infection in a typhoid-mouse model, and this resistance is not 
specific to flagellated Salmonella [60]. Finally, TLR5 knockout mice demonstrate higher 
levels of basal expression of certain innate immunity genes and of IgG and IgA, 
indicating constitutively active immune responses may protect mice in the typhoid model 
[60].  The complicated role of TLR5 uncovered by the TLR5-deficient mouse 
demonstrates the need to further characterize the exact downstream signaling pathways to 
understand how Salmonella interacts with its host.   
TLR signaling may also promote Salmonella infection.  In one study utilizing a mouse 
model of gastroenteritis, Salmonella relied on induction of host pro-inflammatory 
responses to target host normal microbial flora to optimally colonize the host [61].  This 
may reduce competition for Salmonella, allowing the bacteria to gain better access to host 
cells and promote invasion.  In another study, while the researchers did not look 
individually at TLR5, they showed signaling by other TLRs induced vacuolar 
acidification and consequently, provided a cue to induce bacterial virulence factor 
expression and secretion by intracellular Salmonella [62].  Clearly, TLR5 signaling may 
lead to varied host responses to Salmonella infection, depending on the route and site of 
inoculation, highlighting the need for a more thorough understanding of Salmonella-
induced signaling pathways.    
 
NF-κB Signaling 
One of the major transcriptional nodes activated downstream of all TLR signaling is NF-
κB.  NF-κB was originally discovered as a transcription factor utilized during B 
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lymphocyte development, but was later recognized as a broad transcriptional activator 
used in numerous situations.  NF-κB now refers to a family of multiple transcription 
factors that act as master regulators and integrators of host innate immunity and as 
promoters of inflammation as well as general cellular responses to stress and cellular 
differentiation and development.  Specific receptors including TLRs, Tumor Necrosis 
Factor Receptor (TNFR), and Interleukin-1Receptor (IL-1R) signal through NF-κB to 
activate target genes involved in cytokine production, cell adhesion, immunoreceptors, 
and additional transcription factors [63].  NF-κB signaling pathways can generally be 
divided into two types: canonical and non-canonical signaling [64].  Canonical NF-κB 
signaling includes the typical inflammatory-associated NF-κB signaling and occurs on a 
much shorter timescale than non-canonical signaling [64].   
The NF-κB family consists of 5 proteins with a Rel homology domain (RHD): RelA, 
RelB, cRel, p50 and p52 [63].  These monomers are capable of associating via their 
RHDs into 15 potential homodimers and heterodimers [63].  The primarily used NF-κB 
dimer in the canonical pathway is the RelA-p50 heterodimer, where RelA contains the 
transactivating domain [63].  In a resting state, the NF-κB heterodimer is held in the cell 
cytoplasm by one of three classical IκB proteins, IκBα, IκBβ, or IκBε, which bind NF-κB 
through their ankyrin repeats domain (ARD) [63].   When an upstream receptor, such as a 
TLR, is activated, signal transduction pathways lead to activation of IKK kinase 
complexes containing IKKγ , IKKα and IKKβ [63].  Activated IKK phosphorylates IκBα, 
which induces recruitment of an E3 ubiquitin ligase [63].  IκBα is ubiquitinated and 
subsequently degraded by the proteasome, leaving the nuclear localization signal (NLS) 
of the NF-κB dimer unmasked [63].  NF-κB translocates to the host nucleus, where it 
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activates host genes involved in management of stress response and inflammation as well 
as its own negative regulator IκBα, making this a classic negative feedback loop [63]. 
Because NF-κB is such a crucial regulator in host innate immunity, Salmonella has 
evolved multiple mechanisms to evade host detection and activation of NF-κB.  First, the 
organization of flagellin itself is such that the immunogenic portion is predominantly 
hidden in the polymerized protein [53].  It seems Salmonella has evolved a way to mask 
the majority of flagellin’s immunostimulatory activity as it is polymerized on the 
bacterial surface.  Salmonella also secretes multiple effectors capable of down-regulating 
NF-κB signaling.  One of these, SspH1, translocates to the host nucleus, where it inhibits 
NF-κB transcriptional activation [65].  Another Salmonella effector protein, AvrA, is also 
injected into the host cell cytoplasm by the SPI-1 TTSS and seems to play an important 
role in reducing host proinflammatory signaling [66, 67].  Although its exact mechanisms 
are not fully understood, it blocks NF-κB activity, perhaps by acetyltransferase activity 
on downstream players in the NF-κB pathway [66, 67].   NF-κB represents a potential 
block to a productive Salmonella infection, and to compensate, the pathogen positions 
considerable resources into the development of an anti-NF-κB response.   
1.4 Salmonella Interactions with Neoplastic Host Cells 
The Inflammation-Cancer Axis 
Overactive NF-κB signaling can have dire consequences for the host, indicated by the 
multiple mechanisms in place that keep its activity in check.  Perhaps the most important 
tactic used by the host to control NF-κB signaling is NF-κB’s direct transcriptional 
activation of its own negative regulator.  Activated NF-κB induces transcription of IκBα, 
which, after translation in the cytoplasm, is thought to translocate to the nucleus, bind 
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NF-κB, and export the transcription factor [68].  The RelA subunit of NF-κB has also 
been demonstrated to interact with histone deacetylasese (HDACs), which are known to 
negatively regulate transcription [69]. Further, once activated, the NF-κB signaling 
pathway resists further stimulation [70].  In one study, NF-κB activation was measured 
after a TNFα preconditioning step [70].  Following a 30-second exposure to TNFα, IKK-
mediated NF-κB activation was severely compromised for up to 120 minutes, indicating 
that cells can be desensitized to NF-κB stimulatory activity, thus preventing over-
response [70].   
However, even with mechanisms in place to prevent over-stimulation of NF-κB, cells 
exposed to excessive amounts of proinflammatory stimuli may experience deleterious 
effects.  Chronic and overactive inflammation has long been suspected as a contributing 
factor to cancer development, and recently, more information on how infection and 
inflammation may lead to carcinogenesis has emerged.  Collectively, infections and 
inflammation may be at least part of the underlying cause of up to 20% of all cancer 
deaths [71].  There are several known clinical associations between infection or 
inflammation and cancers including Hepatitis viruses HBV and HCV in liver cancers, 
Helicobacter pylori in gastric cancers and the link between inflammatory bowel diseases 
(IBDs) and colorectal cancers, as well as leukemia and other cancers caused by human T-
lymphotropic virus (HTLV) [72-74].  Additionally, there is evidence of genetic 
polymorphisms within the TLR and IL-1β promoters that positively associate with 
prostate and gastric cancers, respectively [75].   
Because carcinogenesis is a lengthy and undefined process, it is difficult to effectively 
study the cancer-inflammation linkage in the laboratory.  However, several studies have 
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produced convincing examples of how misregulated NF-κB signaling can directly 
contribute to tumor formation.  In a colitis-associated cancer (CAC) model in mice, the 
chemical dextran-sulfate sodium salt (DSS) contributes to tumor formation by damaging 
the mucosal barrier and exposing underlying cells to resident normal flora bacteria.  
Inactivation of IKK-β in enterocytes of this model reduced tumor number by 80%, clearly 
indicating a role for the NF-κB pathway in tumor induction in this system [76]. In another 
model system, the mdr2 knockout mouse, the lack of an mdr2 transporter causes 
accumulation of lipids and bile acids within hepatic cells, which results in spontaneous 
tumor formation within 8-10 months [77, 78].  However, when the IκB super repressor 
blocks signaling, tumor formation was blocked as well, indicating cellular stress mediates 
tumor development through NF-κB signaling [77].  In another study, Oguma et al link the 
TNF secreted by macrophages, presumably a result of macrophage NF-κB signaling 
activation when recruited to the site of a gastric infection, with increased Wnt/β catenin 
signaling and gastric tumor formation [79].  Finally, the protein HIF-1α links bacteria, 
NF-κB and cancer as well.  HIF-1α is a transcription factor that is stabilized and activated 
in conditions of low oxygen [80].  Researchers have recently shown that following 
detection of bacteria and subsequent host activation of innate immunity pathways, NF-κB 
activates HIF-1α transcription, likely in response to the hypoxic conditions replicating 
bacteria induce in their host [80]. Coincidentally, tumors produce low oxygen 
environments as well, indicating that activation of this transcription factor in response to 
bacteria also better equips the host for fitness in a pro-tumor environment.  Between 
epidemiological associations and the new data being uncovered in the laboratory, the link 
between inflammation, infection and cancer is growing.   
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Bacteria as a Cancer Therapeutic: A Historical Perspective 
Interestingly, in addition to being a hypothesized contributor to cancer formation, 
Salmonella has recently received consideration as a potential theraputic for cancer.  
Although the typical route of Salmonella infection is gastrointestinal, which may lead to 
chronic carriage or a systemic infection, Salmonella infections of the host are also 
capable of another unique consequence [4].   Salmonella are capable of colonizing a host 
animal at the site of a tumor in vivo [81]. Notably, a correlation between cancer remission 
and coincident bacterial infection was observed as early as the 14th century [81]. In the 
1800’s, the first intentional use of bacteria to treat cancer has been attributed to Dr. W. 
Busch, who exposed a tumor patient to the bed linens previously used by a patient with a 
Streptococcus infection [82].  Despite rapid tumor shrinkage, the woman contracted a 
severe bacterial infection and died soon thereafter [82].  In later work, Dr. William Coley 
pioneered the use of “Coley’s toxin”, a treatment composed of inactivated bacteria 
including Streptococci and Serratia marcesens [82].  Dr. Coley reported tumor 
regression, perhaps via host systemic responses involving induction of tumor necrosis 
factor [81, 82].  Still, intentional infection with bacteria, especially before the advent of 
antibiotic use, was generally unpredictable and difficult to control [81, 82].  The toxic 
side effects and lack of reproducibility of such treatments eventually led to 
discontinuation of their use [82].   
Salmonella: Localization to Tumors 
Recently, anaerobic and facultatively anaerobic bacteria, among other organisms, have 
been shown to selectively localize to and replicate within malignant tumors. Clostridium, 
Bifidobacteria, Escherichia coli, Listeria, Streptococcus pyogenes and Salmonella have 
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each been used in contemporary studies exploring bacterial-based tumor treatment [82].  
Salmonella appears to affect a diverse set of neoplastic cells or tumors, including: 
melanomas, gliomas and neuroblastomas, renal carcinomas, and cancers of the prostate, 
breast, bladder and colon [82-88].  Using noninvasive bioluminescent imaging to track 
Salmonella expressing plasmid encoded luxCDABE, Yu et al showed that Salmonella 
could report malignant tumor locations in living mice. Salmonella are impressively tumor 
adaptable.  They have been shown to localize in tumors with tumor:tissue ratios up to 
9,000 times that of normal tissue, to localize to tumors in both immunocompetent and 
immunocompromised mice, and to detect and replicate within metastases as well [88, 
89].  In independent work, electron micrographs of excised melanoma tumors detect 
Salmonella within the cytosol of melanoma tumor cells, suggesting bacteria not only 
localize to, but may actually invade, malignant tumor cells [82].  However, it remains to 
be definitively shown how Salmonella behave in the tumor environment.  For instance, it 
is not fully understood whether Salmonella are capable of invading cancer cells or what 
types of cancer cells Salmonella will enter.   Also, it is unclear to what extent the 
molecular mechanisms of Salmonella virulence and the specific gene regulation events 
during interactions with cancer cells recapitulate those utilized during a classical 
Salmonella infection.   
Salmonella as a Potential Cancer Therapeutic 
Cancer is predicted to kill more than 500,000 people in the United States in 2011 [90].  In 
this same year, more than 1.5 million Americans will be newly diagnosed with cancer 
[90].  Unfortunately, despite some notable advances, many patients with cancer still must 
contend with remarkably poor diagnosis and treatment options [91-93].  Diagnosis often 
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occurs far too late in disease progression, after metastases decrease the odds of survival.  
In general, chemotherapy and radiation therapy regimens have significant associated 
systemic side effects.  One way to improve the therapeutic index (overall efficacy vs. 
toxicity) of cancer treatments may be to more specifically localize treatment effects to 
malignant tissues. 
Given its localization to malignant tumors, appropriately engineered Salmonella might 
serve well as an anti-tumor agent.  To date, some such efforts have exploited 
Salmonella’s ability to carry tumor antigens.  Others have aimed to activate the immune 
response to attack tumor cells, independent of the bacteria localization to the tumor site. 
Immunotherapy-based strategies are often restricted by limited knowledge of tumor 
markers and their immunogenicity. Salmonella flagellin has been directly injected into 
tumors in an attempt to slow their growth, a strategy that exploits flagellin as a more 
general immune stimulus [87].  However, this treatment failed to effect growth of a 
weakly immunogenic tumor.  Attenuated Salmonella expressing human IL-2 can also 
retard tumor growth in mice [94].  Yet, while Salmonella-based immunotherapy has 
enjoyed moderate success, utilizing it to treat neoplastic tumors seems contradictory, 
given that such tumors are a noted site of immunosuppression.  It is likely that further 
progress in understanding – and perhaps exploiting – the interactions between bacteria 
and tumors can be made by investigating the mechanisms behind Salmonella interaction 
with host tumors. 
Salmonella Behavior in the Tumor Environment 
Two nonexclusive hypotheses have been proposed to explain Salmonella’s preference for 
survival in malignant tumors.  First, the anaerobic, necrotic, or highly vascular 
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environments in and around tumors may provide bacteria with an advantageous niche for 
growth [95]. Second, the bacteria may selectively replicate in tumors due to immune 
protection.  However, very little is known about whether the bacteria themselves behave 
differently in response to cancer cells.  In particular, it has not been determined how 
neoplastic host cells, in contrast to normal (i.e., non-neoplastic) host cells, might 
specifically trigger Salmonella gene expression.  Neoplastic cells often exhibit notable 
phenotypes, including alterations in cell cytoskeleton, signaling pathways, replication 
patterns, or expression of surface or secreted proteins [96].  In theory, any of these host 
cell factors might modify bacterial gene expression.  Recent findings support the premise 
that neoplastic tumors may well alter Salmonella’s behavior.  For example, in an in vitro 
tumor model system, Salmonella migrate toward and collect in cylindrical aggregates of 
tumor cells [97, 98].  These findings raise the prospect that tumor cells release 
compounds Salmonella can sense and travel toward.  In another study, Salmonella 
recovered from tumors in vivo were more efficient at subsequently attaching to, invading, 
and replicating within colon adenocarcinoma cells in vitro than the parent strain [84]. The 
fact that in vivo passage through a mouse tumor produced a Salmonella strain with an 
enhanced tumor-targeting phenotype suggests that Salmonella can indeed be modified by 
interactions with tumors. Perhaps these phenotypic changes reflect Salmonella gene 
expression events involved in tumor localization, attachment and persistence. 
The seemingly conflicting ideas of Salmonella as both pro-cancer and anti-cancer agent 
leave the state of the field unclear.  Work must be done to clarify how Salmonella 
immunostimulatory activity may lead to cancer-causing environments and what effect 
colonization of the tumor has on bacterial activity.  The dynamic interplay between 
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Salmonella and the host will inform development of future tumor and Salmonella 
therapeutics.   
1.5 Bioluminescence Imaging as Tool to Study Prokaryotes and 
Eukaryotes  
The points addressed above rely on gaining more information on Salmonella interactions 
with its host on a global level.  One powerful, emerging technique, bioluminescence 
imaging (BLI), provides the reliability and throughput necessary to study Salmonella 
behavior much more dynamically than ever before.  BLI is based on the use of eukaryotic 
or prokaryotic encoded luciferase enzymes that catalyze a reaction utilizing ATP, 
oxygen, and a luciferin substrate to produce light.  In eukaryotic systems, firefly 
luciferase from Photinus pyralis is most commonly used [99].  Bioluminescently-tagged 
tumor xenografts have provided a convenient and reliable way to monitor tumor 
progression during therapeutic studies [99]. Also, eukaryotic luciferase can be coupled to 
proteins of interest, and used in studies of signaling pathways, protein stability, and gene 
transcriptional activity [99].   
Several bacterial luciferases are also available, originally from the organisms Vibrio 
harveyyi, Vibrio fischeri or Photorhabdus luminescens [100].  Unlike eukaryotic 
luciferases, which generally require the addition of exogenous substrate for imaging, the 
biosynthetic pathways for the bacterial luciferin substrate are relatively simple and a 
single five gene operon is responsible for both the luciferase enzyme and substrate 
production [100].  Studies of microorganisms in vivo are uniquely suited to BLI and 
bacterial-based imaging strategies encompass in vivo, in vitro and in cellulo reporter 
studies.  This is evident especially when imaging bacterial infection models, since use of 
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a bacterial lux operon allows for BLI in real time, without requiring administration of 
exogenous substrate.  Furthermore, traditional in vivo infection models have required host 
sacrifice and enumeration of microorganisms from individual host organs to determine 
the extent and kinetics of dissemination during infection.  BLI provides a unique 
opportunity to serially monitor infection in a single host over time, often resulting in 
identification of new sites of replication and persistence within an infected animal [99].  
Finally, in the investigation of bacteria as a potential diagnostic and treatment tool for 
cancer, BLI has become a particularly popular technique. In such cases, bacterial 
luciferase has allowed for imaging the localization of bacteria to a tumor in a mouse in 
real time [99].  
1.6 Conclusion of the Introduction 
Salmonella Typhimurium is a well-studied human pathogen.  Emerging from the wealth 
of knowledge on Salmonella and its genetic tractability is the desire to use the pathogen 
in new ways – namely, as a cancer diagnostic and therapeutic tool.  However, Salmonella 
is still a pathogen, and therefore may still produce dangerous consequences within hosts, 
especially one that may be immunocompromised, such as cancer patients.  The answer to 
this challenge is not to abandon Salmonella-based treatment altogether, but to search for a 
deeper understanding of Salmonella-host interactions. Salmonella may prove to be a 
simple, cost-effective and robust tumor treatment technique, but will require further study 
of how Salmonella and the host co-exist to better inform future options.   
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1.7 Figures 
Figure 1-1 
 
Figure 1-1: The Pathogenesis of Salmonella Typhimurium 
Salmonella Typhimurium utilizes two separate Type Three Secretion Systems (TTSS) 
during invasion and pathogenesis of host cells.  Initially, the SPI-1 TTSS induces host 
actin filamentation, resulting in bacterial uptake.   Intracellularly, the SPI-2 TTSS 
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promotes bacterial survival and replication through futher host actin cytoskeletal 
remodeling and SCV maintenance.   
Adapted from: Ibarra J. A., Steele-Mortimer O. (2009). Salmonella-the ultimate 
insider. Salmonella virulence factors that modulate intracellular survival. Cell 
Microbiol. 11, 1579–1586. 
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Figure 1-2 
Figure 1-2:  Toll-Like Receptor Signaling  
Eukaryotic Toll-like receptors respond to extracellular and intracellular foreign antigens, 
resulting in signaling pathway activation and nuclear activation of pro-inflammatory 
transcriptional programming.   
Adapted from:  http://www.cellsignal.com/reference/pathway/pdfs/Toll_Like.pdf 
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CHAPTER 2 
Stably Integrated luxCDABE for Assessment of 
Salmonellae Invasion Kinetics 
2.1 Abstract 
Salmonella Typhimurium is a common cause of gastroenteritis in humans, and also 
localizes to neoplastic tumors in animals.  Invasion of specific eukaryotic cells is a key 
mechanism of Salmonella interactions with host tissues.  Early stages of gastrointestinal 
cell invasion are mediated by a Salmonella type-three secretion system, powered by the 
ATPase invC.  The aim of this work was to characterize the invC-dependence of invasion 
kinetics into disparate eukaryotic cells traditionally used as models of gut epithelium or 
neoplasms.  Thus, a nondestructive real-time assay was developed to report eukaryotic 
cell invasion kinetics, using lux+ Salmonellae that contain chromosomally integrated 
luxCDABE genes.  Bioluminescence-based invasion assays using lux+ Salmonellae 
exhibited inoculum dose-response correlation, distinguished invasion-competent from 
invasion-incompetent Salmonellae, and discriminated relative Salmonellae invasiveness 
in accordance with environmental conditions that induce invasion gene expression. In 
standard gentamicin protection assays, bioluminescence from lux+ Salmonellae 
correlated with recovery of colony forming units of internalized bacteria, and could be 
visualized by bioluminescence microscopy. Furthermore, this assay distinguished 
invasion-competent from invasion-incompetent bacteria independent of gentamicin 
treatment in real time.  Bioluminescence reported Salmonellae invasion of disparate 
eukaryotic cell lines, including neoplastic melanoma, colon adenocarcinoma, and glioma 
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cell lines used in animal models of malignancy.  In each case, Salmonella invasion of 
eukaryotic cells was invC dependent.   
2.2 Introduction 
Eukaryotic cell invasion is utilized by Salmonellae during initial steps of pathogenesis 
(1), and leads to enteric symptoms and disseminated infection.  Salmonellae also localize 
to, and sometimes invade, cancerous tumors in mice (2).  One basic tool for dissecting the 
mechanisms of these bacterial-eukaryotic cell interactions is the in vitro cell invasion 
assay.  
The standard technique to assess Salmonella invasion into cultured cells is the gentamicin 
protection assay (3), which exploits the poor penetration of this antibiotic into eukaryotic 
cells (4).  Specifically, gentamicin is postulated to kill susceptible extracellular bacteria, 
but not “protected” bacteria that have invaded. Presumably, such selective killing permits 
the preferential recovery of intracellular bacteria on subsequent culture of lysed cells. 
Gentamicin protection assays have been used to illuminate genetic and cellular 
mechanisms of cell invasion by Salmonellae (5).  For example, the invC gene in 
Salmonella encodes an ATPase that powers a type-three secretion system, triggering 
eukaryotic actin reorganization and Salmonella invasion of some eukaryotic cell lines (6, 
7). 
Despite their widespread use, standard gentamicin protection assays are technically and 
conceptually limited, because they attempt to quantify the invasiveness of individual 
bacterial strains via direct enumeration of bacterial colony forming units recovered from 
lysed eukaryotic cells.  The lysis and colony forming unit (CFU) determination steps 
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consume time, materials and labor.  Colonies are not necessarily correlated with bacterial 
numbers, so agglomerated organisms might be under-enumerated.  Additionally, because 
eukaryotic cells must be destroyed to release invaded bacteria, serial evaluations of 
bacterial invasion in a single temporal assay are precluded.  Furthermore, by definition, 
current gentamicin-protection, CFU-based assays of invasion require that extracellular 
bacteria of interest are killed by gentamicin, which is a condition not always met.  
To attempt to address such limitations, we have modified current gentamicin protection 
assays of bacterial invasion into eukaryotic cells, including neoplastic lines, by using 
bioluminescence to report bacterial invasion.  Contag et al.  originally pioneered the use 
of bacteria expressing luciferase to monitor in vitro and in vivo pathogenesis with 
organisms containing plasmid-encoded luciferase (8).  Here, we employ constitutively 
bioluminescent Salmonellae, which contain chromosomally integrated luxCDABE genes 
from Photorhabdus luminescens (9), and imaging systems that sensitively and 
specifically detect bioluminescent Salmonellae (10).  This nondestructive assay requires 
neither eukaryotic cell lysis, nor gentamicin.  Rather, we use bioluminescence to track the 
invasion of lux+ Salmonellae into various eukaryotic cells in tissue culture. These 
eukaryotic cells include those traditionally used for models of gastroenteritis, as well as 
cells previously used in whole mouse models of metastatic cancers.  To determine the 
invC dependence of invasion kinetics in these different systems, we compare the 
invasiveness of lux+ Salmonellae that are isogenic except for invC.  
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2.3 Methods 
Bacterial Strains and Eukaryotic Cell Lines: The bacterial strains and eukaryotic cell 
lines used in this study are listed in Table 2-1. 
Construction of Salmonellae Strains with Stably Integrated: luxCDABE Conjugative 
mating was performed between donor strain E. coli S17-1 (containing the transfer 
plasmid pUT mini-Tn5 lux Km2; gift of Michael Winson), and recipient Salmonella 
enterica serovar Typhimurium strain SB300A1 (11).  Mating was performed as described 
(12) in Luria-Bertani (LB) broth, then plated onto LB agar, and incubated at 37oC 
overnight.  Mated colonies were scraped from the LB agar, and onto kanamycin (50 
µg/mL) MacConkey agar to discriminate Salmonellae from E. coli. The isolated 
candidate Salmonellae were grown at dilutions of 10-5, 10-6, and 10-7 on these agar plates 
for 48 hours. Replating on LB/kanamycin plates documented the kanamycin resistance of 
the recipients of pUT mini-Tn5 lux Km2.  PCR confirmed the gross presence of each 
gene of luxCDABE in the new strains, but not in the parent Salmonella SB300A1. 
Identification of Site of luxCDABE Integration into the Salmonella Genome:  First, the 
general location of luxCDABE integration was determined from sequences of amplicons 
produced using touchdown PCR (13) of the genomic DNA of our new lux+ Salmonella 
strain. Touchdown PCR used high fidelity Taq DNA polymerase (Invitrogen), and 
thermal cycling conditions (95oC for 5 minutes; then 25 cycles of 95oC for 45 seconds, 
annealing at variable temperature for 45 seconds (60oC in the first cycle and, at each of 
the 24 cycles, decreased by 0.5oC per cycle down to 47.5oC), and extension at 72oC for 2 
minutes). This was followed by 25 cycles of 95oC for 45 seconds, 50oC for 45 seconds, 
and 72oC for 2 minutes. Primer pairs included a degenerate primer 
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CCGAATTCCGGATNGAYKSNGGNTC (where N=A, C, G, or T; Y=C or T; K=G or 
T; and S=C or G), in combination with either an outward facing luxC or luxE primer 
(outward luxC: CCATCTTTGCCCTACCGTATAGAG and outward luxE: 
TGAGGATGAAATGCAGCGTA). Sequence data from the resulting amplicons 
suggested luxCDABE integration between Salmonella chromosomal genes acrB and hha. 
The precise integration site of luxCDABE was then identified.  PCR amplification from 
the genomic DNA of our new lux+ Salmonella strain was performed using two sets of 
primers. One reaction, which produced an amplicon of approximately 2.5kb,  used luxE 
(TGAGGATGAAATGCAGCGTA) and hha (GCCAGAACGAGGAGGCAGATAACA) 
primers, and PCR conditions of 94oC for 3 minutes; 30 cycles of 94oC for 30 seconds, 
51oC for 30 seconds, 72oC for 3 minutes; and 72oC for 7 minutes. The second reaction 
produced an amplicon of approximately 3kb, with luxC 
(ATCCAATTGGCCTCTAGCTTAGCC) and acrB (ACCTCAACGGATGAGTTTGG) 
primers, and PCR conditions directly above.  These amplicons above were sequenced by 
the Protein and Nucleic Acid Chemistry Laboratory at Washington University in St. 
Louis. Sequences were aligned with the Salmonella enterica serovar Typhimurium strain 
LT2 complete genome sequence (14). 
Growth Curves in Liquid Culture: Otherwise isogenic Salmonellae with and without 
chromosomal luxCDABE were grown in overnight liquid cultures then diluted 1:10 into 
fresh liquid media for growth curve analysis. Growth was assessed via serial optical 
transmission measurements.  For growth curve analyses, growth media was Luria-Bertani 
(LB) broth, and incubation was at 37oC in a shaker incubator at 200-250 rpm. 
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Construction of an In-frame invC Deletion Mutant of luxCDABE+ Salmonella:  An in-
frame excision of invC nucleotides between 506 and 590 was performed using the 
pCVD442 suicide vector,  engineered as previously described (15), for gene allele 
exchange (16).  Here, 5’ and 3’ segments of invC were amplified from wild-type invC+ 
Salmonella SB300A1 (11) by PCR using the respective primer pairs 
5′GGAGCGAGCTCACTGCAATATCTGGCCTACCCACA3′ with 
5′GGAGCAAGCTTATCAGCATGGTCTTACCGCATCCT3′; and 
5′GGAGCAAGCTTGGATATGTTGCGCGCTTCGCATAA3′ with 
5′GCTATCTCGAGTTTCGCCAGGACGATATTCTCCCA3′. These four primers 
contain SacI, HindIII, HindIII, and XhoI sites, respectively, and nucleotides (underlined, 
above) of the published Salmonella LT2 genomic sequence for invC (14). The resulting 
PCR products were digested with SacI and HindIII, or with HindIII and XhoI, 
respectively; then individually cloned into pBSIISK+. Following digestion of these two 
plasmids with SacI and HindIII, or with HindIII and XhoI, respectively, the small 
fragments were cloned in tandem into SacI and XhoI digested pBSIISK+, producing 
pBSIISK+(invCΔ506-590). Finally, the SacI delimited insert of pBSIISK+(invCΔ506-
590) was ligated into SacI linearized suicide plasmid pCVD442 (16).  The resulting 
pCVD442(invCΔ506-590) was transformed into E. coli SM10(λpir) (17).  Mating was 
performed between the donor SM10(λpir) strain and the bioluminescent chromosomal 
luxCDABE+ Salmonella strain SB300A1FL6 on LB agar. The cells were then scraped 
from the LB plates and serial dilutions (to 10-7) were made in LB. 100 µL of the dilutions 
were spread on MacConkey agar containing ampicillin (100 µg/mL) and kanamycin (50 
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µg/mL) to select merodiploids.  Of 30 merodiploid candidates, five were picked and 
grown overnight in LB media without salt. These cultures were then plated on 5% 
sucrose plates and incubated overnight at 30oC to select for sacB removal. Presumptive 
sacB deficient colonies on sucrose plates were further screened on LB ampicillin (100 
µg/mL) plates for a phenotype consistent with concomitant excision of the bla gene. One 
such ampicillin susceptible clone was analyzed by PCR amplification using invC flanking 
primers. The resulting amplicon was sequenced, to confirm the anticipated 84 nucleotides 
deletion from the 1296 nucleotide long invC, between invC nucleotides 506 and 590. The 
invC mutant also includes a six nucleotide HindIII site introduced as a byproduct of 
subcloning steps above (i.e., TGCTGATAAGCTTGGATAT, with invC nucleotides 506T 
and 590G underlined).  Accordingly, the predicted InvC protein encoded by our invC 
mutation is missing intact InvC amino acids 169 to 197, and has an isoleucine-serine-
leucine insert encoded by the TAA/GCT/TGG sequence created by the HindIII site insert. 
This invC mutant does not create a frame shift; so should not have polar effects on 
adjacent genes. 
Invasion Assays:  Standard gentamicin-protection assays were performed as described 
(18).  Salmonellae grown overnight in LB broth (37oC) were diluted 1:100 or 1:10 and 
grown to an OD600 of between 0.45 and 0.7, with OD600 matched across samples for a 
given experiment. Incubations were not shaken, except where noted, and as previously 
described (19). These bacteria were diluted 1:10 in DMEM, or to a multiplicity of 
infection of 100 where noted.  
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Diluted bacterial suspensions were added to tissue culture plates, at 500 µL to each well 
in 24 well plates, or 100 µL to each well in 96 well plates.  For 60 minutes, the bacteria 
were coincubated with adherent tissue culture monolayers at 60 to100% confluence.  
Wells were then washed with DMEM and treated with media containing gentamicin at a 
final concentration of 100 µg/mL.  The antibiotic-containing media was replaced with 
phenol-red free media after 90 minutes of treatment and bioluminescence was measured 
three and a half hours later (five hours after the initiation of gentamicin treatment), unless 
otherwise noted. Gentamicin-free conditions represented use of phenol-red free DMEM 
lacking gentamicin after the wash step; imaging occurred three hours after washing.  
In the CFU recovery assay, following bioluminescence imaging, bacteria were quantified 
by CFU recovery after immediate lysis of tissue culture cells with detergent lysis as 
described (McKinney et al., 2004).   
Measurement of Bioluminescence: Bioluminescence measurements were performed as 
published (20-22).  Images were captured with a cooled CCD camera (IVIS 100, Caliper, 
Hopkinton, MA).  Acquisition parameters were:  exposure time, 30s; binning, 8; no filter; 
f/stop, 1; FOV, 15 cm. Signals were measured as the radiance (photons/second/cm2/sr).  
To calculate the bioluminescence from a given well, total photon flux (photons/second) 
was determined from a region-of-interest (ROI) positioned over the given well and an 
empty well, which was subtracted to correct for background machine noise using Living 
Image (Xenogen) and Igor Pro (WaveMetrics) Software. Bioluminescence was presented 
as mean ± standard deviation of the mean of the total photon flux for replicate well 
assays. 
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Bioluminescence Microscopy: Henle cell monolayers cultured on glass bottom 35 mm 
dishes, with or without luxCDABE+ Salmonellae, were treated as described for 
gentamicin protection invasion assays. Two to three hours after Salmonellae inoculation, 
these plates were examined on an inverted microscope (Nikon TE 2000-S) housed in a 
light tight microscope incubator (In Vivo Scientific) with temperature maintained at 
36ºC. Bioluminescence was recorded with a cooled intensified CCD camera 
(XR/MEGA10-AW, Stanford Photonics) controlled by Piper Imaging software version 
1.3.6 (Agile Automation). Due to high amplification of the signal (gain set at 400,000), 
camera noise was reduced during image acquisition by setting a minimum threshold for 
the signal that was kept constant for all cultures. Fifteen image sequence frames were 
obtained per second and integrated later in 40 min stacks to obtain a single image. 
Integration, pseudo-color processing and color merge were performed with ImageJ 
(National Institutes of Health, USA) and Photoshop CS2 (Adobe) software. 
2.4 Results 
Chromosomal Integration of luxCDABE  To create a Salmonella strain that 
constitutively produced bioluminescence, a Tn5 transfer plasmid was used to engineer a 
strain with chromosomal integration of the luxCDABE operon without disrupting 
essential genes in this process.  Independent PCR assays, followed by amplicon DNA 
sequencing, defined the luxCDABE integration site in the Salmonella chromosome 
(Figure 2-1). According to Salmonella strain LT2 complete genomic sequence 
annotation convention (14), luxCDABE in our Salmonella integrated at nucleotide 
528,771, twenty nucleotides 5’ to the start codon of ybaJ. 
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Despite some preference for insertion at G/C pairs (23), Tn5 is considered to mediate 
near-random integration into bacterial genomes (24).  Interestingly, in bioluminescent 
Salmonellae produced by another laboratory using the same suicide vector system, the 
transposon is reported to have integrated at hha (25). Given that hha is immediately 3’ to 
ybaJ in the Salmonella genome, perhaps there is preferential integration of the Tn5 
luxCDABE element into the Salmonella genome near ybaJ / hha.   
Alterations in hha gene expression, secondary to luxCDABE integration, in principle 
could alter pathogenesis, because Hha negatively regulates hilA (26), and hilA regulates 
the invasive phenotype of Salmonellae (27). However, our new luxCDABE+ Salmonella 
does not exhibit decreased hha mRNA levels, assessed by RT-PCR, compared to its 
parent (data not shown). 
Fitness and bioluminescence of luxCDABE+ Salmonellae  The growth curves of 
otherwise isogenic Salmonellae with and without luxCDABE were identical in LB broth 
(data not shown).  As predicted, the Km2 kanamycin selection marker integrated with 
luxCDABE did not bestow resistance to gentamicin at concentrations of 100 µg/mL (data 
not shown).  Furthermore, the kanamycin resistance and bioluminescence phenotypes of 
our luxCDABE+ Salmonellae were stably maintained without kanamycin selection, both 
in long term in vitro cultures and in mouse infections (data not shown).  
Invasion Competence of luxCDABE+ Salmonellae  To determine the impact of 
integrated luxCDABE on Salmonella invasiveness, we performed parallel standard 
gentamicin protection assays with equal inoculations of otherwise isogenic Salmonellae, 
differing only in the presence or absence of chromosomally integrated luxCDABE.  Based 
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on numbers of bacterial colony forming units from lysed eukaryotic cells, there was no 
defect in Salmonella invasion because of luxCDABE integration (data not shown).  
Bioluminescence as a Reporter of Invasion by luxCDABE+ Salmonellae  As 
determinates of host cell invasion, we compared Salmonellae bioluminescence assays and 
colony forming units (CFU) from standard gentamicin invasion assays in tissue culture 
wells. Following measurement of bioluminescence signals from invasion assay tissue 
culture wells, we processed the tissue culture wells to obtain CFU data from the same 
assay wells that had been imaged for bioluminescence.   We lysed the eukaryotic cells 
and used plate counts to recover and enumerate Salmonellae CFU. There was 
concordance between bioluminescence output and CFU recovery in gentamicin 
protection assays (Figure 2-2). Furthermore, bioluminescence readily discriminated 
between invasion-competent and invasion-incompetent luxCDABE+ Salmonellae strains.  
The protein encoded by invC is an ATPase that powers a type-three secretion system, 
triggering eukaryotic actin reorganization and Salmonella invasion (6, 7).  
Bioluminescence distinguished between otherwise isogenic chromosomal luxCDABE+ 
Salmonellae strains that had an invC gene that was either intact (invC+), or ablated by an 
in-frame deletion (invC-) (Figure 2-2). Our invC- strain is more than 200-fold less 
invasive compared with isogenic invC+ Salmonella concordantly assessed by standard 
gentamicin protection assay (6, 7, 18). 
Salmonella invasiveness can also be modified by varying environmental conditions. For 
example, entry into eukaryotic cells can be significantly enhanced when invasion 
competent Salmonellae are prepared using standing rather than shaken cultures (19). 
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Using a bioluminescence-based gentamicin protection assay, we could discriminate these 
invasion phenotype differences for invC+ Salmonellae that differ only in culture 
conditions prior to exposure to eukaryotic cells (Figure 2-3). By contrast, the otherwise 
isogenic invC- Salmonella remained minimally invasive when prepared in either standing 
or shaken cultures (Figure 2-3). 
We reproducibly observed bioluminescence enhancement with increasing Salmonella 
inoculum (Figure 2-4). In standard gentamicin protection assays, the multiplicity of 
infection often requires optimization (3). In the bioluminescence assay, we detected wild 
type Salmonella invasion into eukaryotic cells over a twenty-fold range in multiplicity of 
infection (Figure 2-4). 
Salmonella Invasion into Diverse Eukaryotic Cells: Dependence on invC  
Salmonellae often invade eukaryotic cells postulated to be relevant to cell-cell 
interactions during pathologic intestinal infections (e.g., Henle intestinal epithelial cells 
(3), HT29 colon carcinoma cells (28)). Salmonellae also localize to cancerous tumors in 
animals (2, 29, 30), including non-intestinal cells, such as melanoma, glioma, breast and 
prostate neoplastic cells. Salmonellae can be recovered from these tumors, and in some 
cases appear by electron microscopy to have invaded the neoplastic cells (2). Here, we 
examined the ability of Salmonellae to invade various cells used for models of 
malignancy in mice. Our wild type bioluminescent Salmonella invaded not only Henle 
(Figure 2-2) and HT29 colon cells, but also eukaryotic cells of diverse origins, including 
colon adenocarcinoma MC38, melanoma B16F10 and even, albeit to a lesser extent, 
glioma C6 cells. In each case, this invasion depended on invC (Figure 2-5).   
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Real-Time Kinetic Measurements of Bioluminescence During Invasion Assays  The 
nondestructive nature of bioluminescence now permits serial assessments of the same 
invaded cells over time. We assessed the kinetics of Salmonella bioluminescence from 
single wells of C6 glioma cells during invasion assays. The bioluminescence from a 
given well reflects several factors, including Salmonella cell numbers and viability. At a 
given time, Salmonella viability is influenced by the effects of gentamicin and the 
protection from gentamicin killing afforded by Salmonella invasion into eukaryotic cells.  
Bioluminescence versus time is shown in Figure 2-6. In this experiment, the distinction 
between bioluminescence of invC+ versus invC- Salmonellae was most pronounced five 
hours after initial inoculation. 
Salmonella Invasion Assay, With and Without Gentamicin Protection  Our ability to 
distinguish invasion-competent from invasion-incompetent Salmonellae at time points 
soon after adding gentamicin (Figure 2-6) raised the possibility that bioluminescence 
could assess invasion independent of gentamicin protection per se.  Accordingly, rather 
than gentamicin treatment, we employed a washing step with three rounds of gentamicin-
free media to physically deplete noninvaded Salmonella from the assay wells.  In assays 
in which gentamicin was not used, invC-dependent invasion competence of Salmonellae 
could still be readily resolved (Figure 2-7). While overall assay time was shorter, the 
background activity was higher. 
Bioluminescent Salmonellae Visualized by Cooled CCD Microscopy.  Traditionally, 
bioluminescent bacteria have been most extensively exploited for imaging studies of 
bacterial spread within whole animals, such as for Salmonellae infections manifesting as 
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gastroenteritis or disseminated infections (8, 25), or for the targeted localization of 
Salmonellae to malignant tumors (29). By contrast, for microscopic level studies of 
bacterial localization (30) or gene expression (31), fluorescent rather than bioluminescent 
bacteria have been most widely used. Given recent advances in cooled CCD cameras and 
our interest in tracking luxCDABE Salmonellae microscopically, we attempted to 
visualize our luxCDABE+ Salmonellae using a cooled CCD bioluminescence 
microscope.  Compared to uninfected eukaryotic cell controls, tissue cultures inoculated 
with luxCDABE+ Salmonellae with intact invC exhibited foci of bioluminescence, with 
maximal intensity foci clustered near or within eukaryotic cells (Figure 2-8).  For 
luxCDABE+ Salmonellae lacking invC, the number and intensity of these foci at the 
single cell level were much reduced (data not shown).  The ability to use microscopy to 
visualize invasion by our bioluminescent Salmonellae provides an additional advantage 
as bioluminescent microscopy does not require potentially cytotoxic excitation light and 
typically has low background signal.   
2.5 Discussion 
We report a new constitutively bioluminescent Salmonella strain (SB300A1FL6).  We 
have subsequently deleted (in frame) specific segments of invasion competence genes in 
this primary luxCDABE+ Salmonella strain, creating a set of reagents to study the 
functions of specific Salmonella genes during bacterial-host interactions. In our 
Salmonellae clones, luxCDABE was apparently maintained at low fitness cost.  This 
contrasts with other Salmonellae strains that have been engineered to be constitutively 
fluorescent via the presence of green fluorescent protein.  For example, green fluorescent 
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proteins can significantly inhibit Salmonella growth in epithelial cells and macrophages 
(32), and increase Salmonella doubling time (33).  
Plasmid-based lux constructs have been exploited as reporter systems for bacterial 
location in vitro and in vivo (8, 29).  However, plasmid-based lux systems can suffer from 
instability. Using the pLITE lux expression plasmid in Salmonella infections of mice, loss 
rates of plasmid (and bioluminescence) exceeding 95% of bacterial colonies have been 
reported (29).  We observed no loss of bioluminescence of our chromosomal 
luxCDABE+ Salmonellae strains after serial passages in bacterial cultures or after 
prolonged infections in mice, even in the absence of kanamycin selection to maintain the 
luxCDABE / kanamycin resistance gene insert. 
One motivation for constructing and characterizing these luxCDABE+ Salmonellae 
strains was to use bioluminescence to assess Salmonellae invasion kinetics into 
eukaryotic cells.  Herein, we described a robust and versatile eukaryotic cell invasion 
assay using chromosomal luxCDABE+ Salmonellae.  The new assay correlated well with 
the standard detection methodology over a broad inoculum range.  The bioluminescence 
assay readily discriminated the invasion competencies of invC+ and invC- Salmonella.  
Indeed, the resolution between invC+ and invC- organisms was reliable across a twenty-
fold range of bacterial inoculated dose and multiplicities of infection.  By contrast, CFU-
based assays are notably non-linear with respect to the number of inoculated bacteria (3).  
Bioluminescence-based invasion assays also resolved invasion differences among lux+ 
Salmonellae as regulated by environmental stimuli (19). 
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Bioluminescence-based tracking of lux+ Salmonellae during eukaryotic cell invasion 
permits invasion assays to be performed independent of the stringent requirements of 
gentamicin protection assays. For example, bioluminescence assays need not depend on 
the use of gentamicin to kill extracellular bacteria, or eukaryotic cell lysis to report 
intracellular “gentamicin-protected” bacteria.  This allows studies on bacteria intrinsically 
resistant to gentamicin or enables analysis in growth conditions that compromise 
gentamicin activity (e.g., acidic pH or divalent cation concentrations (34)), as while also 
allowing assays in which gentamicin-mediated effects on eukaryotic phenotypes are a 
concern (35, 36). 
Our assay had similarities to other techniques for assessing bacterial invasion, such as 
direct observation of internalized bacteria following Giemsa staining (37), or direct 
observation of gfp labeled bacteria within eukaryotic cells via fluorescent microscopy 
(30) or FACS analysis (31). However, luxCDABE encoded bioluminescence provided 
potential advantages to detect intracellular bacteria.  For example, in contrast to Giemsa 
staining of inanimate features of bacterial cell walls, or to gfp based fluorescence, lux 
bioluminescence only reported bacteria that were alive and biochemically active (38). 
This direct detection of living bacteria removed the lag time and intermediate maneuvers 
imposed by experiments that rely on bacterial staining or recovery of bacterial CFUs for 
data.  The real-time and non-destructive nature of lux-based tracking of Salmonellae in 
eukaryotic cells also allowed serial measurements from the same well over time. Hence, 
it was well-suited to kinetic studies of bacterial invasion and intracellular survival.  From 
a technical perspective, bioluminescence-based detection of lux+ Salmonellae should 
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readily allow high throughput experimental scaling in multiwell plate assays, with 
readout times within minutes. 
Furthermore, the components of the experimental system described here for studying 
bacterial invasion into eukaryotic cells in tissue cultures can also be used to 
noninvasively detect and localize luxCDABE+ Salmonellae during infections in living 
mice (data not shown).  Thus, bioluminescence-based detection of lux+ Salmonellae 
presents opportunities to more directly correlate in vitro and in vivo models of bacterial-
host interactions.  This can be used to detect Salmonellae in experimental mouse models 
of infection and malignancy. Intriguingly, our bioluminescent Salmonellae invade a 
disparate range of malignant eukaryotic cells in vitro, each in an invC-dependent manner.  
This suggests that Salmonellae interactions with eukaryotic neoplastic cells may 
recapitulate features of Salmonellae interactions with eukaryotic epithelial cells in the 
host intestinal tract. 
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2.7 Tables 
Table 2-1:  Strains and eukaryotic cell lines used in the study 
Strain or Cell Line Description Source or 
reference 
Salmonella  
SB300A1 
Parent Strain, not bioluminescent. Contains araC-
PBAD regulated T7 RNA polymerase. 
Reference 
(11) 
Salmonella  
SB300A1FL6 
SB300A1, modified by chromosomal integration of 
luxCDABE to be constitutively bioluminescent 
This study 
Salmonella  
SB300A1FL6AM1 
SB300A1FL6, modified by in-frame excision of 
invC nucleotides between 506 and 590 
This study 
E. coli  
S17-1 
Donor strain in conjugation with SB300A1, for 
delivery of pUT mini-Tn5 lux Km2 
Reference 
(12) 
E. coli SM10(λpir)  Donor strain in conjugation with SB300A1FL6, for 
delivery of plasmid pCVD442(invC506-590) 
Reference 
(17) 
Henle 407 Human epithelial cell line ATCC:  
CCL-6 
B16F10 Murine melanoma cell line  ATCC:  
CRL-6475 
HT29 Human colon carcinoma cell line ATCC:  
HTB-38 
C6 Rat glioma cell line ATCC:  
CCL-107 
MC38 Murine colon adenocarcinoma cell line Gift: N.O. 
Davidson 
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2.8 Figures 
 
Figure 2-1 
 
 
 
Figure 2-1: Foreign DNA integration site into Salmonella genome, at nucleotide 
528,771.  Nearby loci are acrB, ybaJ, and hha, flanking the insert site of luxCDABE and 
Km2 as shown. The following DNA sequence from the chromosome of our 
bioluminescent Salmonella identifies the junction between Salmonella genomic DNA 
(non-italics, corresponding to Salmonella LT2 genome nucleotides 529,230 to 528,771) 
and foreign DNA (italics, with luxC coding nucleotides 1-163 in underlined italics): 
AAGGCCGCGCAAGCGGCCTTTTTTACGCAAAAATCATAAAATACGCTTAT
TGTTAGATTGATTATTTTTTGCCATATTAATAAAAGGTATAATCCTTACTG
CGTTAAAGGCTTTTCTTAGGAAAGTTGGCCATTTCTTAATTCAGCCATTA
ATTAAGAAATATTAAGAATATTCCTGGCTATTTTCTCCTGTCAGAGTCTA
TTGTTTTAGCCTGAAAAGCTAAAAAACGTTAACCCAATGATTACACAAAC
AATAAAACTGGTTCCTTTTTAGGCGACCGACGATCACTGTTAAAATTCGA
AAAAGTATGGCAACACGCGGCTTTCACGCAATTGTAATTTTTAGTAATAT
GACGATGAAAAGTTTTTTAGAGTAGATTATAGTTAAATCATAAGGTGACG
TGGGAAGTACCAGGTTAGTTAGTTGTATCCATCCCGAAGGTGTTCGGTT
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AGTTTAAGCCCTGACTCTTATACACAAGTGCGGCCGCGTTTAAACCCATGGACGT
GTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACTCAGGGCC
CACTAGTGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGTCGACGGATCCGG
GGAATTCAGGCTTGGAGGATACGTATGACTAAAAAAATTTCATTCATTATTAACGGC
CAGGTTGAAATCTTTCCCGAAGGTGATGATTTAGTGCAATCCATTAATTTTGGTGAT
AATAGTGTTTACCTGCCAATATTGAATGACTCTCATGTAAAAAACCATTATTGATTGT
AATGGAAATAACGAA 
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Figure 2-2 
 
Figure 2-2: Comparison of colony forming unit (CFU) recovery and 
bioluminescence (photon flux, in photons/second) from gentamicin protection assays 
using bioluminescent Salmonellae that vary only by invC gene status.  Data from a 
representative gentamicin protection assay performed in triplicate wells are shown.  Here, 
invasion of Henle epithelial eukaryotic cells was assessed by bioluminescent Salmonellae 
either with invC (wild type, invC+) or without invC (invC-). In each case the multiplicity 
of infection was 100.  CFUs report Salmonellae grown from lysates, per single wells in a 
24 well plate.  Photon flux is in units of photons/second, also per single wells in a 24 well 
plate.  CFU and photon flux results are shown as means (+/- SD). A representative pair of 
wells from the bioluminescence-based assay is shown with adjacent wells containing 
either invC+ (left well) or invC- (right well) luxCDABE+ Salmonellae; the pseudo-color 
scale denotes photon intensity radiance. Similar results were obtained in experiments 
using HT29, rather than Henle eukaryotic cells (Figure 2-5 and data not shown). 
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Figure 2-3 
 
Figure 2-3. Bioluminescence and gentamicin protection following differing 
Salmonella growth conditions known to induce enhanced Salmonella invasiveness. 
The bar graph compares bioluminescence data obtained from a bacterial invasion assay of 
HT29 eukaryotic cells by bacteria previously grown in cultures that were either shaken or 
standing.  Standing cultures are known to induce enhanced Salmonella invasiveness in 
cell culture, as compared with shaken culture conditions (19). Induction state is as 
indicated. Photon flux data are shown as means (+/- SD), in units of photons/second, and 
were obtained 90 minutes after adding gentamicin. 
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Figure 2-4 
 
 
Figure 2-4. Bioluminescence signal intensity correlated with Salmonella inoculum 
dose.  Photon flux signals from invasion assays of HT29 cells across a 20-fold dilution 
range of invasion competent (invC+) bioluminescent Salmonella.  Because eukaryotic 
cell numbers per well were constant, this also corresponds to 20-fold range of multiplicity 
of infection. In wells lacking eukaryotic cells, photon flux signals approach ambient 
background. Results are from quadruplicate samples, with photon flux data (in units of 
photons/second) shown as means (+/- SD).  
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Figure 2-5 
 
Figure 2-5. Invasion of bioluminescent Salmonellae into eukaryotic cell lines of 
diverse origins. Photon flux data represent invasion of wild type invC+ and invC- 
Salmonellae into human intestinal HT29, mouse colon adenocarcinoma MC38, mouse 
melanoma B16F10 or rat glioma C6 cell lines.  For invC+ bioluminescent Salmonellae, 
the photon signal following exposure to glioma eukaryotic cells was approximately one-
tenth that seen with adenocarcinoma cells (note different y-axis scale for glioma cells). 
Data are from triplicate wells, shown as means (+/- SD), in photons/second. 
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Figure 2-6 
 
Figure 2-6.  Kinetics of bioluminescence during Salmonellae infection.  Photon flux 
data of bacteria serially measured from the same invasion assay wells. The times 
indicated hours after initiation of a 90 minute gentamicin treatment followed by 
replacement with media. Salmonellae invC+ and invC- strains, and C6 glioma eukaryotic 
cells, are as described above. Data are from triplicate wells, shown as means (+/- SD), in 
units of photons/second. 
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Figure 2-7 
 
Figure 2-7. Bioluminescence monitoring of Salmonella interactions with eukaryotic 
cells, using gentamicin-containing and gentamicin-free media.  Photon output from 
invC+ and invC- Salmonellae invasion of Henle cells, from quadruplicate samples, with 
photon flux data shown in units of photons/second, expressed as means (+/- SD).  
Gentamicin-treatment conditions represented 90 minutes of gentamicin incubation, 
following replacement with phenol-red free DMEM media, and imaging at 5 hours after 
initiating gentamicin addition.  Gentamicin-free conditions represented use of phenol-red 
free DMEM media lacking gentamicin throughout, followed by three washes; imaging 
occurred three hours after washing. 
 
 58 
Figure 2-8
 
Figure 2-8. Microscopic detection of bioluminescence from luxCDABE+ Salmonella 
in eukaryotic cell cultures.  Henle cell monolayers are shown either alone (left panels) 
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or following inoculation with luxCDABE invC+ Salmonella (right panels). For each 
sample, images show the bioluminescence signal alone (top), the phase contrast (bottom), 
and a merged image of bioluminescence and phase contrast (middle).  Within the merged 
image of the Henle cells inoculated with luxCDABE Salmonella, a box demarcates the 
image area enlarged in the upper right corner (inset). Yellow arrows outline a Henle cell; 
maximal intensity foci occur near or within eukaryotic cells. Spectral scales denote 
pseudo-color representation of bioluminescence signal intensity in relative light units 
(RLU), ranging from 1 to 50 RLU for samples without Salmonella, and 1 to 100 RLU for 
samples with Salmonella. Processing of these samples followed the same methods as 
gentamicin protection assays described in the text; images were obtained two to three 
hours after inoculation of Salmonella. Bar = 50µM.  
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CHAPTER 3 
 
Cancer Cell–Induced Transcriptional Response of 
Salmonella Typhimurium Visualized with a 
Bioluminescent Transposon Reporter-Trap  
3.1 Abstract 
Salmonella specifically localize to malignant tumors in vivo, a trait potentially exploitable 
as a cancer drug delivery system. To characterize mechanisms and genetic responses 
of Salmonella during interaction with living neoplastic cells, we custom designed a 
promoterless transposon reporter containing bacterial luciferase. Analysis of 7,400 
independent Salmonella transposon insertion mutants in co-culture with melanoma or 
colon carcinoma cells identified five bacterial genes specifically activated by cancer cells, 
adiY, yohJ, STM1787, STM1791, and STM1793. Further experiments identified acidic 
pH, a common characteristic of the tumor microenvironment, to be a strong, specific and 
reversible stimulus for Salmonella gene activation in vivo and in vitro. Finally, a 
Salmonella reporter strain expressing a plasmid encoding the luciferase transgene driven 
by the STM1787-inducible promoter showed tumor-mediated transgene activation in vivo, 
demonstrating the potential for a new bacterial-based cancer therapeutic. Salmonella, 
which often encounter acidic environments during classical host infection, may co-opt 
evolutionarily conserved pathways for tumor colonization in response to the acidic tumor 
microenvironment. Therefore, specific promoter sequences may provide a platform for 
Salmonella-based tumor therapy with two inherent levels of target specificity in vivo. 
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3.2 Introduction 
Salmonella Typhimurium is a Gram-negative bacterium and a common human 
gastrointestinal pathogen. In human hosts, the organism is typically acquired by ingestion 
of bacteria causing a gastroenteritis that may progress to a systemic infection. Salmonella 
Typhimurium, characterized by its ability to invade host cells, utilizes genes from two 
chromosomally-encoded pathogenicity islands, SPI-1 and SPI-2, which contain genes 
encoding two separate type-three secretion apparatuses, as well as suites of effector genes 
and various transcription regulators. Research has uncovered important functions during 
both cell invasion and disease pathogenesis for many of these virulence genes.  
Recently, new research has indicated that Salmonella, in addition to its ability to cause 
gastrointestinal disease, may be utilized as a potential diagnostic or therapeutic reagent 
for malignant tumors. Using bioluminescent and fluorescent bacteria, previous research 
has shown that intravenously delivered Salmonella are remarkably capable of localizing 
to and persisting within xenograft tumor models in vivo  [1]. The ability of Salmonella to 
localize to tumors is impressive, as it has been shown that Salmonella bacteria are 
capable of colonizing and persisting in tumors at rates 10,000 times greater than 
colonization of other organs [2]. Salmonella localize both to metastases and tumors, and 
show specific replication in tumors for weeks in vivo [1, 3]. Studies have also utilized the 
genetic tractability of the organism to design strains that cause little widespread damage 
to their hosts while retaining the ability to target and persist within tumors [3, 4]. 
At least two popular hypotheses are proposed to describe the Salmonella tumor-targeting 
phenotype. The first assumes tumors are a relatively immunoprotected site within a host 
animal, and bacteria may survive specifically in the privileged microenvironment of the 
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tumor, whereas in other normal tissues are cleared by the host’s immune system. The 
second hypothesis proposes that bacteria are attracted by chemotactic factors to a necrotic 
environment wherein the availability of excess nutrients in the tumor facilitates 
replication within this site. To this end, Kasinskas, et al., has shown that bacteria tend to 
accumulate in specific regions of an in vitro tumor model and this behavior is based on 
nutrient sensors and the chemotaxis machinery [5, 6].  
Compared to investigations of the Salmonella pathogenic cycle, few experiments have 
investigated the specific genetic responses of Salmonella to eukaryotic tumor cells and 
bacterial mechanisms regulating this unusual and interesting detour from the typical 
disease route. In the present work, we engineered a bioluminescent transposon reporter-
trap to screen a Salmonella Typhimurium library for genes specifically regulated by co-
culture with malignant cells in vitro. Five genes were identified by the screen and their 
promoter sequences were found to be specifically activated by the acidic 
microenvironment associated with cancer cells in vitro and tumors in vivo. Finally, we 
utilized one of the activated promoter sequences to demonstrate proof-of-principle studies 
of Salmonella-based tumor therapy with two inherent levels of target specificity in vivo. 
3.3 Methods 
Bacterial strains and culture conditions:  The Salmonella typhimurium strains SB300A1 
[7], SB300A1FL6 (luxCDABE) [8], luxAB and AM3 (luxCDABE msbB-) were grown in 
LB broth with appropriate antibiotics. SB300A1FL6 is modified by chromosomal 
integration of luxCDABE and is constitutively bioluminescent. The luxAB strain consists 
of SB300A1FL6 with the integrated luxE gene disrupted. This strain does not 
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bioluminesce without addition of exogenous decanal substrate. The AM3 strain has the 
SB300A1FL6 background, but also has an msbB gene disruption, giving it a less 
immunogenic LPS structure. The Tn:27.8 strain, specifically identified from the screen as 
a non-inducible mutant, phenocopies luxAB with constitutive bioluminescence that 
requires exogenous decanal. 
Tissue culture cell lines and culture conditions:  B16F10 murine melanoma cells were 
obtained from ATCC and cultured according to ATCC directions. HCT116 human colon 
carcinoma cells were a gift from Bert Vogelstein and were cultured according to ATCC 
methods.  
Plasmids:   The plasmid pMAAC001 contains the full bacterial luciferase operon 
luxCDABE driven by a T7 promoter and an ampicillin resistance cassette. The plasmid 
pLuxCDE consists of the pMAAC001 backbone amplified using the forward primer 
cccgggattggggaggttggtatgtaa and the reverse primer cccgggtgaatgatttgatgagccaaa (XmaI 
sites underlined). This product was then XmaI digested and re-ligated to exclude the 
majority of the luxA and luxB genes. pLux and pPROMOTERLux plasmids were 
constructed by inserting the full bacterial luciferase operon between the KpnI and BamHI 
restriction sites in the vector puc19. The pPROMOTERLux plasmid additionally had a 
500 base pair promoter region (STM1787) from the Salmonella genome inserted 
upstream of the luciferase operon between the SacI and KpnI restriction enzyme sites. 
The 500 base pair sequence was amplified from the Salmonella genome using the 
forward primer aaagagctcatttgtcgagagctgggatg and the reverse primer 
aaaggtacccaggaaacggcattggtaat (SacI and KpnI sites underlined).  
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Construction of a Salmonella Typhimurium reporter-trap library:  Salmonella strain 
SB300A1 was used to construct a bacterial library comprising approximately 7400 clones 
of unique chromosomal integrations of our reporter transposon [7]. The custom Tn5-
based transposon was designed with the EZ-Tn5 system (Epicentre, Madison, WI) using 
the pMOD4 transposon construction vector. A kanamycin-resistance cassette and 
promoter from EZ-Tn5<KAN-2> was amplified using the forward primer 
acgacaaagcttggacgcgatggatatgttct and the reverse primer agcttttctagaggtggaccagttggtgattt 
(HindIII and XbaI restriction sites underlined) and inserted into the HindIII and XbaI 
restriction sites of pMOD4. The luciferase enzyme genes luxAB from Photorhabdus 
luminescens were amplified with the forward primer acagtcgaattccgccgaatgagaattgagat 
and the reverse primer aagctgggtacctgttggctgctttcactcac (EcoRI and KpnI sites 
underlined) and inserted between the EcoRI and KpnI sites in pMOD4 [8]. The plasmid 
contained an R6Kγ origin of replication and therefore was amplified in E. coli DH5α 
λpir, purified, digested with Pvu II, and the transposon fragment recovered by gel 
purification. The purified transposon was combined with transposase (Epicentre). After 
bench top incubation for 30 minutes, followed by 48 hours at 4°C, the transposon DNA 
was electroporated into bacteria as per the vendor’s instructions. Bacteria were plated on 
LB kanamycin plates to select for transformants containing the chromosomally-integrated 
transposon. Each clone was expanded and stored in 60% glycerol in 96-well plates at -
80°C. 
Screening the library:  To screen for gene activation events occurring in the context of 
malignant cells, Salmonella library clones were cultured under three different conditions: 
co-culture with B16F10 mouse melanoma cells, co-culture with HCT116 human colon 
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carcinoma cells and culture in media alone. Each of the two tumor cell lines were seeded 
into 96-well white plates at approximately 70-80% confluency in DMEM with 10% FBS. 
In the plate containing media alone, each well contained 100 μl of DMEM with 10% FBS 
only. Plates were incubated overnight to allow tumor cell adhesion to the 96-well white 
plates. Independently, bacterial clones were grown overnight in LB broth with kanamycin 
in 96-well plates and subcultured the following day 1:10 into LB broth. Five to six hours 
after subculturing, 30 μl of bacterial culture were added to three replicate plates, each 
corresponding to a separate culture condition. Bacteria were allowed to co-incubate with 
the malignant cells or media alone for 2 hours. Subsequently, bacteria were imaged by 
adding 30 μl of decanal solution, waiting 10 minutes, and imaging with an IVIS 100 
imaging system (Caliper; acquisition time, 60 sec; binning, 4; filter, < 510; f stop, 1; 
FOV, 23 cm) [9]. Because white plates were used to maximize signal intensity, images 
were aquired utilizing a <510 filter to reduce phosphorescence from the plates. Three 
control wells were included on every plate comprising:  luxCDABE Salmonella 
(SB300A1FL6), which contain the full luciferase operon inserted into the chromosome; 
luxAB strain, which contains the luciferase enzyme genes only and therefore requires 
addition of exogenous substrate to image reporter activity in the assay; and a blank well, 
which contained media, but was not inoculated with bacteria, to serve as a control for 
background luminescence. Imaged plates were analyzed with Living Image (Caliper) and 
Igor (Wavemetric) analysis software packages as described[10]. Data were normalized by 
dividing the photon flux of experimental wells by media alone wells and presented as the 
log2 of the normalized photon flux data. 
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Identification of hits:   Library screening data representing photon flux from each well of 
a library plate were analyzed with Image J software [11]. To identify statistically 
significant hits from the primary screens, we utilized a set of statistical requirements. 
First, a threshold was set to identify active clones. Clones that did not produce photon 
signals greater than three standard deviations above the signal in the un-inoculated, media 
alone wells were not further analyzed. A quartile method of statistical analysis was then 
applied to the remaining clonal data [12]. For quartile analysis, plates of clones were 
grouped by assay date into sets for data analysis. For each set, we normalized data by 
calculating the log2 of the fold-change of photon flux signal between the condition of 
interest (co-culture with B16F10 or HCT116 cells) and media alone. From this data, we 
calculated the median (Q2), first (Q1), and third (Q3) quartile values. The boundary for 
hit selection was calculated as Q3 + c(ICQ), where ICQ=Q3-Q1 and c = 1.7239, 
corresponding to a high stringency targeted error rate of α = 0.0027 [12]. 
Verification of primary screen hits: To verify hits identified by the primary screen, clones 
were tested again in a similar manner, in quadruplicate. The assay followed the same 
steps as those in the primary screen, except each clone was tested in 4 wells under each of 
three conditions across a 12-well row in a black 96-well plate. Imaging was done with an 
IVIS 100 imaging system (acquisition time, 60 sec; binning, 4; filter, open; f stop, 1; 
FOV, 23 cm). 
Identification of transposon insertion site: To map sites of transposon integration in the 
chromosome of clones of interest, an inverse touchdown PCR strategy was used [13]. 
Genomic DNA was isolated from bacteria using DNAzol (Molecular Research Center, 
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Cincinatti, Ohio). PCR was performed using bacterial chromosomal DNA, 20 pmols of a 
primer specific to the 5’ end of the transposon (atggctcataacaccccttg), and 100 pmols of a 
degenerate primer (cggaatccggatngayksnggntc). Reactions were initiated with a 95°C 
preparation step for 5 minutes, followed by 25 cycles comprising denaturation at 95°C 
for 45 seconds, annealing at various temperatures for 45 seconds and extension at 72°C 
for 2 minutes. The annealing temperature started at 60°C and decreased 0.5°C per cycle 
for the subsequent 24 cycles. Then PCR proceeded with 25 cycles of 95°C for 45 
seconds, 50°C for 45 seconds and 72°C for 2 minutes. PCR reaction products were 
fractionated on a 1% agarose gel, and the most prominent bands in each lane were 
excised and gel purified (Qiagen kit). For some reactions, PCR products were purified 
(Qiagen) and the resulting purified PCR product was used as a template for a second 
round of PCR using a different transposon-specific primer (aacatcagagattttgagacacc) 
before gel purification of products. The cycling conditions and degenerate primer used in 
the second round of PCR were the same as round one.  
Semi-quantitative RTPCR:   Salmonella strain SB300A1 was subcultured from a 
stationary phase culture 1:10 and grown for 6 hours. Bacteria were then diluted 1:20 and 
added to 96-well plates containing tissue culture media alone or B16F10 melanoma cells, 
seeded 24 hours previously at 100,000 cells/well. After three and a half hours of co-
culture, extracellular media containing bacteria were removed from the 96-well plates 
and triplicates pooled. Media were centrifuged to pellet bacteria and pellets were frozen 
at -80°C. After thawing, pellets were resuspended in 200 μl water with 5 mg/ml lysozyme 
and incubated at room temperature for 5 minutes. Then, 700 μl of RLT buffer was added 
and bacterial RNA was purified using the Qiagen RNeasy kit (Qiagen Inc, Valencia, CA). 
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Samples were then treated with DNase I at room temperature for 15 minutes, after which 
EDTA was added and samples were incubated for 10 minutes at 65°C to inactivate the 
DNase. Samples were then ethanol precipitated and resuspended in 30 μl water. For 
reverse transcriptase PCR, 1 μg of total RNA was used as a template and reverse 
transcribed using Superscript II Reverse Transcriptase and 300 ng random primers as per 
the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Following RTPCR, samples 
were treated with RNase H for 25 minutes at 37°C. To perform semi-quantitative PCR, 
samples were amplified using primers specific to each gene target or to ribosomal RNA: 
STM1787 (forward: tcggtagatcgcatgatgtc, reverse: ggttggtcataagcctgtcg), STM1791 
(forward: acacgggaacatccagattc, reverse: cggcaaaggacaaatctcat), STM1793(forward: 
ttcggcaacctgtttttagg, reverse: acgcctccttgcataatcac), adiY (forward: ccttattgaccgccaactgt, 
reverse: gtggtcaagaaagcgggata), yohJ (forward: caggcatttttcttgcatca, reverse: 
cgccatataacgaatcagca), rrsH (forward: cagccacactggaactgaga, reverse: 
gttagccggtgcttcttctg). PCR cycling conditions were: 95°C for 5 minutes, 30 cycles (or 20 
cycles for rrsH reactions) of denaturation at 95°C for 45 seconds, annealing at 50°C for 
45 seconds and extension at 72°C for 1 minute. PCR products were fractionated on a 1% 
agarose gel.  
Construction of deletion mutants: Mutant strains deficient for the identified target genes 
were constructed in Salmonella strain luxCDABE msbB- (AM3), which contains a 
constitutively active, chromosomally-encoded bacterial luciferase operon as well as a 
mutation in msbB to create a less immunogenic LPS structure. Mutants were constructed 
using a lambda red recombinase strategy [14]. First, primers were designed to amplify the 
chloramphenicol-resistance cassette in pKD3 with tails flanking the targeted locus of the 
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Salmonella genome to be deleted. Primer sequences specifically targetting the genome 
for each mutant were used (adi forward  targetting  primer:  
atgaaagtattaattgttgaaagtgagtttctgcatcaggacacctgggtgtgtaggctggag-ctgcttc, adi reverse 
targetting primer:  atcctgtttaaccggcgcatccagcggatacgggtttttgtgaatgc-
ggtcatatgaatatcctccttag; yohJ forward  targetting  primer:   agtaagtcactgaatattatctg-
gcaatatatacgcgcttgtgtaggctggagctgcttc, yohJ reverse  targetting  primer:   ttttttcgttcc-
cttctgcccaaccactttacgctcaccgcatatgaatatcctccttag; STM1789-1793 forward  targetting  
primer: atgaatgcgcaacgcgtagtggtgatggggttaggaaaccgtgtaggctggagctgcttc, STM1789-1793 
reverse  targetting  primer: ctaataaagttcatgatcgttgcggcggagggtccccaggcatatgaa-
tatcctccttag). PCR fragments were then electroporated into AM3 bacteria expressing 
plasmid-encoded red recombinase. Following electroporation, growth on 
chloramphenicol plates at 37°C selected for strains that had lost the temperature-sensitive 
recombinase plasmid and inserted the chloramphenicol-resistance cassette into the 
targeted genomic loci. Deletion of the genes was confirmed by PCR.  
Dose-response to tumor cells: To test the dose-response of hits from the screen to tumor 
cell co-culture, the assay was performed as described, except that either B16F10 or 
HCT116 cells were plated at 1x105; 2 x105; or 3 x105 cells per well 24 hours before co-
culture with bacteria. Stationary phase bacteria were diluted 1:50 and incubated for 6 
hours before identical aliquots were allowed to co-culture with the malignant cells. 
Imaging was done with an IVIS 100 imaging system (acquisition time, 10 sec; binning, 8; 
filter, open; f stop, 1; FOV, 20 cm). Imaged plates were analyzed with Living Image 
(Caliper) and Igor (Wavemetrics) analysis software packages as described [10]. 
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Assaying promoter activation in different pH media:  Stationary phase bacteria were 
subcultured 1:100 into LB broth. Five to six hrs after subculturing, 10 μl of bacterial 
culture were added to 190 μl pre-warmed HEPES-buffered media in black 96-well plates  
adjusted to different pH values, and allowed to incubate for three and a half hours. 
Bacteria were then imaged with an IVIS 100 imaging system (acquisition time, 60 sec; 
binning, 8; filter, open; f stop, 1; FOV, 20 cm).  
Mouse imaging studies: To generate tumor xenografts, 6-week old nu/nu mice (Taconic) 
were injected subcutaneously in the right flank with 1 x106 B16F10 cells or 2.5 x106 
HCT116 cells in 100 μl PBS. Tumors were allowed to grow for two (B16F10) or three 
(HCT116) weeks before bacterial challenge. Saturated cultures of strain AM3 and 
deletion mutant bacteria were subcultured 1:100 into LB and grown for 3 hours. Bacteria 
were then diluted to 1 x106 bacteria/ml and 100 μl were injected via tail vein. Mice were 
imaged as indicated using an IVIS 100 imaging system (acquisition time, 60 sec; binning, 
8; filter, open; f stop, 1; FOV, 20 cm). Photon flux data were calculated by utilizing user-
determined regions of interest (ROIs) around bioluminescent tumors with Living Image 
software.  
For in vivo promoter inducibility experiments, 6-week old nu/nu mice (Taconic)  were 
injected subcutaneously in the right  and left flanks with 1 x107 HCT116 cells in 100 μl 
PBS. Tumors were allowed to grow for one week. Saturated cultures of Salmonella strain 
SB300A1 containing plasmids pMAAC001, pPROMOTERLux, or pLux were 
subcultured 1:100 into LB and grown for 3 hours. Twenty microliters of bacterial culture 
were injected intratumorally. Mice were imaged as indicated using an IVIS 100 imaging 
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system (acquisition time, 180 or 60 sec; binning, 8; filter, open; f stop, 1; FOV, 25 cm). 
Photon flux data were calculated by utilizing software-determined regions of interest 
(ROIs) around bioluminescent tumors with Living Image software.  
Tumor ex vivo imaging:  6-week old nu/nu mice (Taconic) were injected subcutaneously 
in the right flank with 1 x105 B16F10 cells and tumors allowed to grow for two and a half 
weeks. Saturated cultures of bacteria were diluted and 5 x105 bacteria were injected 
intratumorally. At 24 and 48 hours following bacterial injections, mice were sacrificed, 
and tumors excised and dissected into 4 sections each. The bacterial-colonized tumor 
sections were incubated in HEPES/Tris-buffered media at the indicated pH values and 
imaged using an IVIS 100 imaging system at the indicated times (acquisition time, 180 
sec; binning, 8; filter, open; f stop, 1; FOV, 12 cm).  
Statistics: Error bars represent the standard error of the linearly regressed data or the 
standard error of the mean where noted.  
3.4 Results 
To conduct a large-scale, unbiased screen for genes up-regulated by contact with 
malignant cells, we used a Tn5-based transposon as the backbone of a LuxAB reporter 
construct. We chose to use the bacterial luciferase enzyme genes (luxAB) only, in contrast 
to the full bacterial luciferase operon (luxCDABE), because the size of the transposon 
containing the full operon prohibited efficient chromosomal integration, while using only 
the luxAB genes allowed for efficient genomic insertion of the transposon. The 
transposon was designed to restrict reporter gene expression to only those chromosomal 
integration sites downstream of an active promoter. A kanamycin resistance cassette with 
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a constitutive promoter was also included to select for integration into the chromosome 
(Figure 3-1a). After construction, the purified transposon was electroporated into 
Salmonella Typhimurium strain SB300A1 for random chromosomal integration, 
producing a 7,400 clone bacterial library[7].  
Initially, the entire Salmonella library was subjected to a primary screen in the context of 
three conditions: tissue culture media alone, B16F10 melanoma cells and HCT116 colon 
carcinoma cells, both of the latter in monolayer co-culture with the Salmonella reporter 
library. The eukaryotic tumor cells were grown in 96-well plate format overnight and 
then bacterial clones added to wells corresponding to each of the two co-culture 
conditions and media alone. After a two-hour incubation, bioluminescence imaging of 
plates enabled identification of clones specifically up-regulating genes in the context of 
exposure to melanoma and/or colon carcinoma cells (Figure 3-1a). Results of the screen 
from co-culture with melanoma and colon carcinoma cells are shown in Figures 3-1b 
and 3-1c, respectively. In each case, data are shown as a rank-ordered S-plot of the log2 
of the normalized signal for each clone of the library, where normalized signal was the 
ratio of the signal in the condition of interest to the signal in media alone. The majority of 
data points clustered around zero, indicating that most mutants interrogated in the assay 
did not show tumor-specific gene regulation. However, quartile analysis with a boundary 
for hit selection corresponding to a high stringency targeted error rate (α = 0.0027) 
identified five candidate mutants wherein the transposon reporter was specifically up-
regulated during co-culture with malignant cells. 
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Following the primary screen, we utilized inverse touchdown PCR to map the specific 
location of each transposon in the Salmonella genome [13]. Table 3-1 documents the site 
of chromosomal integration for the transposon and candidate gene up-regulated in each 
isolate. All genes were novel in that they have not been previously reported to be 
involved in Salmonella-host interactions, nor involved in Salmonella colonization of 
neoplasia. Interestingly, the genomic insertion sites of the transposon in three of the 
clones inserted in a cluster in the chromosomal sequence. Mapped to three different, but 
closely linked genes (STM1787, STM1791 and STM1793, respectively), two are known 
hydrogenases, and all three genes are likely co-regulated and involved in the same 
Salmonella function. Although three integrations in the same putative operon may seem 
to indicate a transposon insertion bias, this is not likely.  Because the transposon insertion 
library contained more than 7400 individual mutants, the average distance between two 
different transposon integration sites was therefore approximately 650 base pairs 
throughout the entire Salmonella genome. In the case of the three transposon insertions 
discussed above, integration sites were located 2843 base pairs (STM1787 and STM1791) 
and 2185 base pairs (STM1791 and STM1793) apart, indicating random integration by the 
Tn5-based system could easily have produced this result. Sequencing showed that in one 
high stringency hit, the transposon had inserted into adiY, a Salmonella gene known to be 
involved in an acid tolerance response [15]. The transposon in the fifth clone was 
identified to have landed in yohJ, a putative membrane protein [16]. 
To validate cancer cell co-culture-specific gene activation events identified in the primary 
screen, we first repeated the co-culture assay in quadruplicate in at least three 
independent experiments for each clone. Figure 3-2a shows the data from one 
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representative experiment for clones verified by this assay. Again, all five clones showed 
statistically significant enhancement of bioluminescence in the presence of tumor cells, 
with a trend toward greater gene up-regulation when co-cultured with B16F10 melanoma 
cells. Then, to further characterize tumor cell-induced response of Salmonella, we 
utilized the tumor cells in a dose-response assay (Figures 3-2b, c). Additionally, to verify 
that the reporter activation seen in the Salmonella reporter-trap clones was not an effect 
of differing substrate permeability due to mutations in bacterial genes, the bacteria used 
in this assay contained the original chromosomal luxAB insertion as well as a plasmid 
constitutively expressing luxCDE, the biosynthetic genes for the long-chain aldehydes 
that act as the optical substrates of the bacterial luciferase operon. Therefore, for this 
assay, it was not necessary to add decanal to the media. Identical innoculations of 
bacteria showed greater up-regulation of the reporter when exposed to greater numbers of 
tumor cells in co-culture conditions, indicating that the stimuli from tumor cells 
instigated a graded response from the bacteria. Because expression of the lux operon 
genes fully complemented the use of exogenous decanal in the system, the data 
confirmed that the effect was not an artifact of exogenous decanal permeability in the 
primary screen.  
Finally, to verify that the reporters in fact reflected mRNA transcriptional regulation in 
wild-type Salmonella during co-culture with tumor cells, we utilized semi-quantitative 
PCR. Following a three-hour co-culture of wild-type (SB3001A1) bacteria with B16F10 
cells or in tissue culture media alone, isolated RNA was reverse transcribed to cDNA. 
Semi-quantitative PCR of the cDNA showed co-culture with B16F10 melanoma cells 
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enhanced the intensity of target gene transcripts, but not of the control ribosomal RNA 
transcripts (rrsH) (Figure 3-2d).  
Notably, of the genes identified in this screen, at least one, adiY, has previously been 
reported to be up-regulated in acidic pH conditions [15]. One characteristic of tumor 
microenvironments in vivo is an abnormally acidic pH [17]. For these reasons, the 
Salmonella transposon insertion mutants were further investigated for reporter signal 
activation in acidic conditions. Figure 3-3 shows that reporter signals increased in acidic 
pH media compared to neutral media. Each of the clones up-regulated the reporter gene 
at pH 6.0 compared to the physiological pH of normal body tissue (pH 7.5), suggesting 
that the stimulus Salmonella responded to in the context of neoplastic cells was 
microenvironment acidification. 
To determine whether the activated genes were required for localization to tumors or 
required for colonization and growth within tumors in vivo, Salmonella strains mutant for 
genes identified in the screen were constructed. Selected genes were deleted using a 
lambda red recombinase insertional deletion strategy, which inserted a chloramphenicol 
resistance cassette into the targeted genes. The deletion mutants were created from a 
parental Salmonella strain (luxCDABE msbB-) containing a chromosomally-integrated 
and constitutively-expressed bacterial luciferase operon for imaging bacterial 
localtization in vivo in real time. The stain also contained a msbB gene deletion, which 
causes a less immunogenic LPS structure and minimizes septic shock effects when the 
strain is administered intravenously [3]. Based on the analysis that the identified 
STM1787, STM1791 and STM1793 genes were contained in a single operon, we targeted 
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a large region of this operon for deletion in a single mutant strain, 1789-1793-. The gene 
adiY also appeared to be a part of a larger operon of co-regulated genes and was therefore 
targeted along with the adjacent genes adi and yjdE. The gene yohJ was targeted 
individually. In a B16F10 melanoma tumor xenograft model, all bacterial strains were 
injected via mouse tail vein and deletion mutants compared to the parental strain for 
localization to and persistence within the tumor using bioluminescence imaging (Figure 
3-4). All mutant strains and the parent strain were capable of tumor localization and 
persistence, indicating that the identified genes were not essential for bacterial 
colonization of the tumor. The experiment was also performed in an HCT116 colon 
carcinoma xenograft model with similar results. Table 3-2 details the numbers of mice 
with colonized tumors on or before day 10 in each experiment.  
We next sought to demonstrate the specificity of selected promoter activation in the 
tumor microenvironment in vivo. Here, we used the constitutively bioluminescent 
Salmonella strain Tn:27.8+pluxCDE or the conditionally bioluminescent strain 
Tn:1787+pluxCDE, each of which constitutively express plasmid-encoded luxCDE, but 
the latter strain will only bioluminesce upon activation of the chromosomally-encoded 
luxAB reporter. In a B16F10 melanoma tumor xenograft model, bacteria were injected via 
mouse tail vein or intratumorally and allowed two days to localize and adapt to tumors in 
vivo. Tumors were then excised, incubated in solutions of various pH values and imaged 
periodically for six hours. Initially, all tumors showed bioluminescent bacteria ex vivo. 
Over time, constitutive Tn:27.8 Salmonella showed an increase in signal consistent with 
bacterial growth in the tumor explants. This behavior was also observed in the Tn:1787 
Salmonella-infected tumor suspension in low pH media. By contrast, when the Tn:1787 
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Salmonella-infected tumor was maintained in basic media conditions throughout, the 
signal initially increased, but then plateaued around 4 hours and decreased in comparison 
to the constitutively bioluminescent Tn:27.8 strain (Figure 3-5). This finding indicated 
that bacterial gene expression was initially engaged by the low pH conditions of the in 
vivo tumor microenvironment, but after exposure to a higher pH environment ex vivo, the 
promoter driving the reporter was repressed and signal declined. Further, this ex vivo 
effect was reversible. When the medium on the Tn:1787 Salmonella-infected tumor 
suspension was changed from pH 6.0 to pH 7.5, the bioluminescent signal decreased. 
Conversely, when the media was changed from pH 7.5 to pH 6.0, the signal increased 
(Figure 3-5b). These effects were not seen with the constitutive Tn:27.8 Salmonella-
infected tumor explants, and provided further evidence in support of the specificity of the 
trapped Salmonella promoter in the Tn:1787 transposon mutant for the tumor 
microenvironment.  
Because the identified Salmonella genes were dispensable for tumor localization, but 
their respective promoters were activated in the tumor microenvironment, these strains 
provided a unique opportunity to design tumor-targeting bacterial vectors subject to 
various levels of controlled specificity. Thus, we sought to determine if the acidic pH of 
the tumor microenvironment could be exploited to specifically activate a target transgene 
during tumor localization. As proof of principle, we constructed Salmonella reporter 
strains expressing plasmids encoding the bacterial luciferase operon driven by either 
constitutive promoters or an inducible promoter to demonstrate tumor-mediated 
transgene activation in vivo. The plasmids pMAAC001 and pLux both encoded 
constitutively-expressed luciferase operons, while the pPROMOTERLux plasmid was 
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engineered to contain the luciferase operon driven by the Salmonella candidate promoter 
(STM1787) comprising 500 base pairs upstream of the putative transcription start site of 
tumor-activated genes STM1787, STM1793 and STM1791 (which we will now refer to as 
the STM1787 promoter). Bacteria expressing these plasmids were identically injected into 
mice bearing HCT116 tumor xenografts on each flank (Figure 3-6). We chose to utilize 
intratumoral injection to directly compare reporter gene activation from two different 
bacterial strains, one inducible and the other constitutive, over time in the same mouse. 
Although reporter signals from pPROMOTERLux-expressing bacteria were low 
immediately after injection into the tumor, the bacteria quickly induced a 90-fold 
enhanced expression of the reporter after an 8 hr exposure to the tumor 
microenvironment (Figure 3-6a). Concurrently, bacteria constitutively expressing pLux- 
or pMAAC001-luciferase showed <20-fold or no reporter activation, respectively, after 
exposure to the tumor microenvironment (Figures 3-6a and 3-6b). These data directly 
demonstrated tumor-specific induction of a transgene from the Salmonella STM1787 
promoter in an in vivo system. Therefore, the STM1787 promoter could be used as a 
platform to design tumor-targeting Salmonella strains capable of specifically delivering a 
therapeutic gene or toxin to the site of a tumor in vivo. 
3.5 Discussion 
Salmonella Typhimurium bacteria are typically classified as human gastrointestinal 
pathogens and a common cause of modern food-borne illness. However, another noted 
characteristic of Salmonella is the bacterium’s coincident colonization of tumor tissue. In 
fact, in the 1800’s, some physicians began to intentionally use bacteria as tumor 
therapeutics. Yet, due to significant toxicity and lack of consistent, reliable results, these 
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practices were abandoned. However, more recent studies using longitudinal imaging 
demonstrate Salmonella colonization of tumors in real time and have sparked a renewed 
interest in this concept using Salmonella [1, 18] as well as various other tumor-localizing 
microbes as an option for cancer treatment [19-25].  
A number of these studies capitalize on utilizing bacteria as treatments per se or as drug 
delivery vehicles, by exploiting their potentially low toxicity and high tractability  [23, 
26-30]. Various attenuated Salmonella strains have been developed for use in tumor-
targeting studies, including specific amino acid auxotrophs and LPS mutants [3, 31]. 
However, the greatly reduced toxicity of Salmonella LPS mutants (msbB-) observed in 
swine models has not been observed in mouse models [32, 33]. In more than one 
instance, attenuated Salmonella have even been used in a clinical trial to treat cancer in 
humans [33-35]. However, trials so far show relatively low rates of tumor colonization in 
human hosts, which may be due to excessive attenuation of bacteria  [32, 36]. 
Additionally, one study indicates that induction of TNFα by bacteria is necessary for 
optimal colonization of tumors [37]. Nonetheless, few studies have investigated the 
phenotypic and gene expression patterns of these tumor-targeting bacteria following 
exposure to tumor cells. 
Tumor-targeting bacteria present a challenge: how to produce a bacterial strain 
sufficiently attenuated to limit side effects, but not so attenuated that tumor colonization 
is unlikely. One approach to this problem is to increase the tumor specificity of the 
treatment strategy. By using bacterial strains containing therapeutic gene products for 
which expression is specifically activated in the tumor microenvironment, it may be 
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possible to reduce the dose of potentially toxic bacteria. However, the ideal location for 
this transgene in the Salmonella genome must demonstrate two critical properties. First, 
the location must be highly up-regulated in the tumor microenvironment. Second, the 
insertion of a gene at this site must not disrupt the ability of the Salmonella to target and 
colonize tumor tissues. Candidate genes that meet the above criteria may serve as ideal 
target sites for inserting therapeutic transgenes. 
In this study, we utilized an engineered transposon to interrogate the Salmonella genome 
for genes activated during exposure to cancer cells. Toward this objective, we generated a 
library of greater than 7,400 independent transposon insertions, which, assuming random 
integration, would predict genomic coverage of approximately 1.5X. From this library, 
we identified five Salmonella genes specifically up-regulated during co-culture with 
cancer cells, STM1787, STM1791, STM1793, adiY and yohJ. Following identification of 
these tumor cell-activated genes, verification in secondary assays and confirmation in 
wild-type Salmonella, we determined that the common stimulus for up-regulation of 
target gene expression was acidic pH. In another study aimed at identifying Salmonella 
promoters involved in tumor colonization in vivo, Salmonella genomic DNA was 
digested and ligated randomly upstream of a GFP reporter. In this study, the major 
stimulus identified in reporter activation was hypoxia, but no pH-regulated promoters 
were identified [38].  While pH and hypoxia are physiologically linked, the five genes 
identified herein show no overlap with the promoters identified by Arrach et. al. [38]. 
The lack of concordance may reflect the different strategies for gene identification or the 
inherent enhanced sensitivity of bioluminescence readouts (due to the lack of background 
signals) compared with fluorescence. Nonetheless, hydrogenase genes are noted in some 
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cases to be up-regulated in low oxygen conditions, indicating that hypoxia may serve as a 
further stimulus for the pH-induced promoters identified in the present study [39]. 
However, in pilot studies using an incubation pouch system used for growing anaerobic 
bacteria, we did not observe any significant changes in transposon reporter activity (KF, 
unpublished data). While these data don't necessarily rule out entirely oxygen-
independence, pH appeared to be the dominant signal inducing responses in the 
promoters identified by our bioluminescent transposon reporter-trap screen. 
In view of the usual pathophysiology of Salmonella, it is not surprising that Salmonella 
strains have gained the ability to precisely regulate genes in response to different pH 
environments. Salmonella encounter low pH conditions regularly during human 
infection, for example, during transit through the stomach, and later during intracellular 
trafficking through the phagosome [40, 41]. Interestingly, the acidic pH of the tumor 
environment in vivo has long been noted as an important microenvironmental condition 
when designing effective tumor treatment techniques [17, 42]. Additionally, the low pH 
environment of the tumor inhibits host defense. Cytotoxic immune cell activity and 
cytokine secretion has been shown to be impaired by a low extracellular pH [43, 44]. In 
contrast, with a bacterial-driven tumor therapeutic, low pH may become an exploitable 
advantage, by adding another level of selectivity to bacterial gene activation. In this case, 
a bacterial-based system may succeed, while both conventional therapeutics and host 
defenses fail.  
When using bacteria as a vector for drug delivery studies, tumor-specific expression is a 
major concern. The genes identified herein are highly expressed in an acidic pH tumor 
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environment, but are not required for bacterial tumor targeting. Therefore, the promoters 
regulating these genes may be ideal candidates for utilization in therapeutic gene, pro-
drug or toxin delivery studies. We have identified the STM1787 promoter as an ideal 
bacterial sequence capable of driving tumor-specific expression of a transgene, and 
demonstrated this in vivo using bioluminescent imaging. By adapting the STM1787 
promoter in Salmonella to drive expression of an appropriate therapeutic transgene, the 
resulting bacterial vector would provide two independent mechanisms for specifically 
targeting tumors. First, Salmonella specifically localize to and accumulate in tumors in 
vivo. Second, the STM1787 promoter is preferentially activated in the acidic tumor 
microenvironment. The combined effect of these two levels of specificity provides a 
potential option to design more successful bacterial therapeutics in the future.  
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3.6 Tables 
 
 
Table 3-1. Transposon chromosomal insertion locations in Salmonella reporter mutants. 
Strain Name Transposon Insertion 
Location 
Base pairs 
Downstream of 
Start Codon 
Function 
(Putative) [16] 
Tn:1787 STM1787  1,189  Hydrogenase 
Tn:1791 STM1791  505  Hydrogenase 
Tn:1793 STM1793  661  Cytochrome 
oxidase 
Tn:adiY adiY  439  araC-like 
transcriptional 
activator; 
arginine-
dependent acid 
tolerance 
Tn:yohJ yohJ  205  Hypothetical 
membrane protein 
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Table 3-2. Tumor localization of constitutively bioluminescent Salmonella mutants. 
Mutant Number of Mice with 
Bioluminescent, Colonized 
Tumors/Total Mice Injected 
(HCT116 Colon Carcinoma) 
Number of Mice with 
Bioluminescent, Colonized 
Tumors/Total Mice 
Injected 
(B16F10 Melanoma) 
Totals 
luxCDABE 2/3 3/4 5/7 
STM1789-1793 2/3 2/5 4/8 
adi 1/2 4/5 5/7 
yohJ 3/3 3/5 6/8 
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3.7 Figures 
 
Figure 3-1 
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Figure 3-1. Design and utilization of a high throughput screen to identify tumor cell-
induced gene activation events in Salmonella. (a) A schematic of the promoter trap 
system using Tn5-based luxAB chromosomal integration. Expression of the promoterless 
luxAB reporter vector, and resulting Salmonella bioluminescence, is dependent on 
“trapping” an active promoter upstream of the chromosomal integration site. The 
transposon was randomly integrated into SB300A1, and kanamycin-resistant colonies 
were selected and arrayed into 96-well plates for library screening. Representative 
primary screening plates in triplicate show responses of Salmonella library strains to 
three separate co-culture conditions: media alone (top), B16F10 melanoma cells (bottom 
left), HCT116 colon carcinoma cells (bottom right). Hit 47.74, showing selective 
activation in co-culture with cancer cells, is indicated by the black open arrowhead, while 
the signals in the upper and central wells represent non-selective activation of clones. In 
each plate, wells H10, H11, and H12 (red box) contain media and bacteria constitutively 
expressing luxCDABE, bacteria constitutively expressing luxAB, and no bacteria, 
respectively, as controls. Primary library screening data from Salmonella promoter trap 
clones co-cultured with B16F10 melanoma cells (b) or HCT116 colon carcinoma cells 
(c). Data are reported as the log2 of the normalized signal for each library clone, where 
normalized signal was the ratio of the signal in the condition of interest to the signal in 
media alone. 
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Figure 3-2 
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Figure 3-2. Verification of Salmonella gene activation events in the context of tumor 
cell co-culture. (a) Salmonella reporter clones displaying gene activation signals during 
co-culture with tumor cell lines (black bars, B16F10 melanoma cells; open bars, HCT116 
colon carcinoma cells). Salmonella strains luxAB and Tn:27.8 contain chromosomal 
luxAB genes under constitutive promoter control; luxCDABE Salmonella contain the full 
luciferase operon inserted into the chromosome; pMAAC001 constitutively expresses 
plasmid-encoded luxCDABE. (b, c) Salmonella reporter clones display dose-responsive 
gene activation in co-culture with B16F10 and HCT116 cells. Bacteria were co-cultured 
with 1x105, 2x105, or 3x105 B16F10 or HCT116 cells/well. Data were normalized as the 
ratio of the signal in the condition of interest to signal in media alone. Error bars 
correspond to SEM. All p value calculations are between luxCDABE and the group 
indicated by the symbol: (*), p ≤ 1x10-7; (x), p ≤ 0.06. (d) Semi-quantitative reverse 
transcriptase PCR with wild-type SB300A1 bacteria verifies that genes identified by the 
reporter transposon screen in Salmonella are activated during co-culture with B16F10 
melanoma cells. rrsH = ribosomal RNA. 
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Figure 3-3 
Figure 3-3. Acidic pH stimulates targeted Salmonella gene activation. Bacteria were 
cultured in media of different pH values and reporter activation by Salmonella library 
clones in low pH media (pH 6) were compared to reporter activation in normal pH (7.5). 
Genes identified in the tumor cell co-culture screen were activated in the context of acidic 
pH compared to pH 7.5. pMAAC001 and luxCDABE constitutively express plasmid-
encoded and chromosomally-encoded luxCDABE, respectively. Data were normalized as 
the ratio of the signal in media pH 6.0 to signal in media pH 7.5. Error bars correspond to 
standard error. The data show one representative experiment with 4 replicates per 
condition tested. All p-value calculations are between luxCDABE and the group indicated 
by the asterisk (*), p ≤ 2x10-14. 
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Figure 3-4 
 
Figure 3-4. Activated genes are not essential for Salmonella tumor localization. Mice 
bearing B16F10 melanoma flank tumor xenografts were injected intravenously with 
constitutively bioluminescent mutant Salmonella. (a) Representative mice on day 10 post 
Salmonella injection. (b) Bioluminescent photon flux of the four mice depicted in (a) as a 
function of time following injection of bacteria.  
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Figure 3-5 
 
 
 
Figure 3-5. The Tn:1787 trapped promoter is specifically and reversibly activated 
by the pH of the tumor microenvironment.  Mice bearing B16F10 melanoma flank 
tumor xenografts were injected intratumorally with tumor-activated (Tn:1787+pluxCDE) 
or constitutively bioluminescent (Tn:27.8+pluxCDE) Salmonella. (a) The excised tumors 
were imaged hourly and data are presented as the normalized signal at each time point. 
The normalized signal represents the ratio of the mean of the fold-initial signal of two 
Tn:1787+pluxCDE-colonized tumors to the mean of the fold-initial signal of two 
constitutive Tn:27.8+pluxCDE-colonized tumors. The data presented are from a 
representative experiment; the experiment was performed independently two times, each 
with two mice per bacterial treatment group. (b) Representative ex vivo tumor imaging 
shows reversibility of the bioluminescent signal in the tumor-activated Salmonella. 
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Images on the left show Salmonella-infected tumor explants after 6 hours of incubation at 
the indicated pH (pH 6.0, top; pH 7.5, bottom). Two hours later (8 hours total), media 
was removed and replaced with media of the indicated pH (pH 7.5, top; pH 6.0, bottom). 
Images on the right show Salmonella-infected tumor explants 4 hours after the pH of the 
media was changed.  
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Figure 3-6 
 
Figure 3-6. The STM1787 promoter in Salmonella is rapidly activated in vivo by the 
tumor microenvironment. (a) A representative mouse with two HCT116 colon 
carcinoma flank tumor xenografts. The left tumor (black arrow) was injected with 
STM1787 pPROMOTERLux-expressing Salmonella, while the right tumor (red arrow) 
was injected with constitutive pMAAC001-expressing Salmonella, and the mouse imaged 
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at the indicated times post-injection. (b) The mean photon flux for each set of 
Salmonella-injected tumors, normalized to the initial signal in each tumor, plotted as a 
function of time. Error bars represent SEM; pPROMOTERLux (n=6); pLux (n=3); 
pMAAC001 (n=3). 
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CHAPTER 4 
A High-Throughput siRNA Screen Identifies Nucleoside 
Diphosphate Kinase (NME3) as a Novel Host Regulator 
of NF-κB Signaling in Response to Salmonella-Induced 
Activation of TLR-5 
 
4.1 Abstract 
Salmonella is a well-known activator of the innate immune system by engaging NF-κB 
signaling.  In this work, we now demonstrate Salmonella-induced IKK activation and the 
resulting NF-κB transcriptional activation in real time.  We show that in HCT116 colon 
carcinoma cells, flagellin is the predominant ligand accounting for Salmonella induction 
of NF-κB.  Then, an siRNA library targeting 691 known and predicted human kinases 
was screened in HCT116 colon carcinoma reporter cells expressing a κB5IκBα-FLuc 
reporter to identify novel host kinase modulators of flagellin-induced NF-κB activation.  
This screen uncovered nucleoside diphosphate kinase (NME3) as a previously 
unrecognized, positive regulator of Salmonella-induced NF-κB signaling.   
4.2 Introduction 
The bacterial pathogen Salmonella Typhimurium commonly causes gastrointestinal 
illness in human hosts and is transmitted by ingestion of contaminated food and water.  In 
the host, the bacteria invade intestinal epithelial cells, causing tissue destruction, 
inflammation and diarrhea.   In some instances, a severe Salmonella infection can 
damage the intestinal barrier so severely that the bacteria penetrate this barrier, invade 
infiltrating phagocytes and progress to a systemic infection.  In order to protect itself 
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against bacterial infections, the host employs a robust set of first line defenses 
collectively referred to as innate immunity.  One important component of host innate 
immunity consists of a series of pattern recognition receptors activated by common 
foreign antigens, or PAMPs (pathogen associated molecular patterns).   These receptors 
include Toll-like receptors (TLRs) and NOD receptors, both of which are involved in 
activation of inflammatory signaling.   
Over the years, multiple TLRs have been identified, several of which are activated by 
Salmonella.  Salmonella is capable of activating TLR2, TLR4 and TLR5 through its 
peptidoglycan (PG), lipopolysaccharide (LPS) and flagellin [1].  Once bound, these 
receptors induce downstream signaling in host cells resulting in activation of pro-
inflammatory pathways, one of which is NF-κB [1].  To initiate NF-κB signaling, TLRs 
induce a downstream kinase cascade that results in activation of IKK, which 
phosphorylates IκBα, the negative regulator of NF-κB[1].   Ubiquitination and 
degradation of IκBα frees NF-κB to translocate into the nucleus and activate downstream 
transcriptional programming to promote inflammation and immune responses [1].   
Salmonella engagement of TLRs and activation of NF-κB serves primarily to alert the 
host of invading pathogens.  However, Salmonella recognition by TLRs may result in at 
least two potentially deleterious downstream effects in host cells.  First, it has been 
shown that Salmonella capitalizes on host TLR activation to induce bacterial virulence 
factor expression, indicating that the bacteria have evolved mechanisms to increase their 
virulence in response to detection by the host cell [2].  Second, NF-κB activation leads to 
pro-proliferative signaling in host cells, and over-activation of these pro-proliferative 
signals has been linked to cancer [3].  Indeed, chronic bacterial infections, including 
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those by Salmonella species, have been linked to carcinogenesis [3, 4].  Therefore, a 
better understanding of the signaling pathways specifically induced during Salmonella 
colonization is necessary to fully understand how to best combat infection.   
In this work, we have identified flagellin as the predominant immunostimulatory PAMP 
of Salmonella-induced activation of NF-κB signaling in HCT116 colon carcinoma cells.  
We then utilized a high-throughput approach to search for previously unidentified host 
modulators of Salmonella-induced NF-κB signaling.  We identified NME3, a eukaryotic 
kinase, as an important regulator of NF-κB signaling activity.   
4.3 Methods 
Cell lines and culture conditions:  HCT116 cells were a gift of Bert Vogelstein and 
cultured according to ATCC directions.  All stably transfected HCT116 cells were 
cultured in 0.5 µg/ml puromycin.   
Salmonella strains: Salmonella Typhimurium strain SL1344 was used for all 
experiments, except where noted.  All mutants (fliC-, fljB- and fliC-fljB-) were 
constructed using a lambda red recombinase strategy [5]. First, primers were designed to 
amplify the kanamycin- or chloramphenicol-resistance cassette in pKD4 or pKD3 with 
tails flanking the targeted locus of the Salmonella genome to be deleted. PCR fragments 
were then electroporated into SL1344 bacteria expressing plasmid-encoded red 
recombinase. Following electroporation, growth on kanamycin or chloramphenicol plates 
at 37°C selected for strains that had lost the temperature-sensitive recombinase plasmid 
and inserted the chloramphenicol-resistance cassette into the targeted genomic loci. The 
double mutant strain was created in a step wise manner, by individually deleting each 
gene.  Deletion of the genes was confirmed by PCR. 
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Creation of a κB5IκBαFLuc-expressing HCT116 stable cell line: HCT116 cells at 95% 
confluency were co-transfected with 10 µg of pκB5IκBαFLuc and 3 µg of pIRES-puro 
plasmid DNA using Fugene 6 in 10 cm dishes.  After 24 hours, the media was replaced 
with fresh cell media.  Twenty-four hours later, the cells were split at multiple dilutions 
into media containing 0.5µg/ml puromycin to select for stable transformants.  After two 
weeks, isolated cell colonies were imaged to check for reporter gene expression and 
bioluminescent colonies were harvested and expanded.  The cells were continuously 
cultured in the presence of 0.5µg/ml puromycin to maintain expression of the reporter 
plasmid.  
Transient transfections of HCT116 cells:  HCT116 cells were transiently transfected 
where noted.  Cells were plated in 24-well (50,000-60,000 cells/well) or 96-well (10,000 
cells/well) plates and transfected with Fugene 6 (Roche) and 200 ng of plasmid DNA(24-
well) or 50 ng of plasmid DNA (96-well) per well. In the case of NME3 over-expression 
experiments, 100 ng of reporter plasmid and 200 ng of over-expression (pCMV6:NME3) 
or vector control (pCMV6) plasmid were used in each well of a 24-well plate.  Cells were 
allowed to recover for 48 hours prior to imaging. 
Dynamic imaging of NF-κB signaling:  Thirty minutes prior to imaging, cell media were 
aspirated and replaced with colorless DMEM supplemented with 10% heat-inactivated 
FBS and 150 µg/ ml luciferin.  To image, cells were stimulated as indicated and imaging 
was performed in an IVIS 100 imaging system (except where noted), with images being 
acquired every 5 minutes for 6 hours, unless otherwise indicated.  The cells were 
maintained in the imaging chamber by a heated stage (37ºC) and 5% CO2 air flow.  
Stimuli included: SL1344 Salmonella Typhimurium , or indicated mutants, confluent 
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culture (final dilution 1:100 in well) or matched for OD600, heat-killed by boiling 10 
minutes and diluted 1:10 into each well (where noted), lipopolysaccharide (1µg/ml) 
(Sigma), peptidoglycan (Sigma), ie-DAP(10µg/ml) (InvivoGen), MDP (10µg/ml) 
(InvivoGen), TNFα (20 ng/ml) (R & D systems), or flagellin (100 ng/ml) (InvivoGen).  
Acquisition parameters are noted in the figure legends.   
High-throughput screen: siRNA screening was performed in white, clear-bottomed, 96-
well culture plates using a Beckman-Coulter Core robotics system, including an FX 
liquid handler, controlled by the Sagian graphical method development tool (SAMI 
scheduling software).  HCT116 cells stably expressing pκB5IκBαFLuc were seeded at 
15,000 cells per well in a 96 well plate and cells were allowed to attach for 24 hours.  
Forward transfection was performed with a 96 multichannel head on the FX liquid 
handler, adding 0.5 µl/well of media-complexed R1 Transpass (NEB) to the aliquotted 
siRNA library (Kinase siRNA set v2; Qiagen Inc.) in a 96-well reaction plate and 
allowed to incubate for 15 minutes. Experimental siRNA oligos were arrayed in columns 
2-11 of each plate and individual controls comprising vehicle-treated wells, a non-
targeting control sequence (Qiagen Allstar Negative control), TLR5-targetting siRNA 
sequences (IDT), and a firefly luciferase-targeting PGL3 siRNA (Dharmacon Research 
Inc.) were placed manually in columns 1 and 12. After incubation of siRNA complexes, 
100 µl was added to each well of a plate with cells (x3 plates) using the FX liquid 
handler, yielding a final concentration of ~50 nM siRNA/well. Plates were maintained at 
37ºC and 5% CO2 for 48 hrs.  At this time, media were aspirated and replaced with 180 
µl imaging media (colorless DMEM supplemented with 10% heat inactivated FBS and 
150 µg/ml d-luciferin) and the cells were allowed to equilibrate for 45 minutes.  After 
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equilibrating, 20 µl of stimulus (1:100 dilutions of heat-killed Salmonella cultures) or 
control (LB broth) were added to each well.  Bioluminescent readings were obtained on 
an EnVision plate reader (PerkinElmer) immediately following the stimulus, at 45 
minutes post-stimulation and at 245 minutes post-stimulation.  After the final luminescent 
reading, 20 µl of rezasurin dye was added to all wells, allowed to incubate for 2 hours at 
37⁰C and monitored on a FLUOstar OPTIMA fluorescence reader for cell viability 
(BMG Labtech; excitation, 544 nm, emission, 590 nm).   
Data analysis:  Initially, the signal in each well was normalized to a plate-matched 
control well containing a non-targeting siRNA sequence at each time point to facilitate 
experiment-wide analysis.  Then, the differences in the log2 values of the normalized data 
between 0 minutes and 45 or 245 minutes were averaged across triplicate siRNA 
experimental replicates.  Then, screening hits were selected by quartile analysis of the 
normalized kinase library data.  To perform the quartile analysis, median (Q2), first (Q1) 
and third (Q3) quartile values were calculated.  From these values, the upper and lower 
boundaries for hit selection were calculated as Q3 + 2c(Q3 –Q2) and Q1 – 2c(Q2-Q1), 
respectively, for c = 1.2245 corresponding to a high-stringency targeted error rate (α = 
0.02) and for c = 0.7193 corresponding to a low-stringency targeted error rate (α = 0.1) 
[6].   
siRNA knockdown:  siRNA knockdown of NME3 was performed utilizing 4 separate 
targeting sequences.  Stably-transfected HCT116 cells were plated in 96-well plates at 
15,000 cells/well and allowed to incubate overnight.  Twenty-four hours later, cells were 
transfected with R1 Transpass (NEB) and 25 nM siRNA (Qiagen) as per R1 Transpass 
instructions.  Cells were incubated for 72 hours prior to imaging. 
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shRNA lentiviral knockdown cell line construction: Lentivirus, expressing constructs 
(pLKO.1 puro), were obtained pre-synthesized from the Genome Sequencing Center at 
Washington University. The targeting sequences for the 3 shNME3 constructs are as 
follows: 
#7 - 5’ GAGGTTGGCAAGAACCTGATT 
#8 - 5’ GCCTTGTCAAGTATATGGCCT 
#9 - 5’CGAGAGGAAGGGCTTCAAGTT 
Additionally, a scrambled shRNA construct was utilized as a negative control.  To 
generate lentivirus containing hairpins, 500,000 293T cells were pre-plated in 60 mm 
dishes and co-transfected the following day with 1 µg of hairpin construct, 900 ng 
packaging plasmid pCMV-ΔR8.2, and 100 ng of envelope plasmid pVSVG using Fugene 
6.  Two days after transfection, virus containing supernatant was collected from 293T 
cells and filtered through a 0.45µm filter, mixed with 5ug/ml protamine sulfate, and 
added to HepG2 cells at 50% confluency in a 10cm2 dish.  Media was replenished 12 hrs 
post-transduction, and cells were subsequently maintained in media supplemented with 
500 ng/ml puromycin hydrochloride to retain expression of the hairpins.  Following 
transduction, shNME3 or shSCRAMBLED cells were plated in parallel for mRNA 
knockdown confirmation and transient transfection and subsequent imaging 
measurements with the κB5→IκBα-FLuc reporter or the κB5→FLuc reporter as 
previously described.  
Semi-quantitative RTPCR:   HCT116 cells transduced with shNME3 or shSCRAMBLED 
hairpins were lysed and total RNA was purified using the Qiagen RNeasy kit (Qiagen 
Inc, Valencia, CA). Samples were then treated with DNase I at room temperature for 15 
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minutes, after which EDTA was added and samples were incubated for 10 minutes at 
65°C to inactivate the DNase. Samples were then ethanol precipitated and resuspended in 
water. For reverse transcriptase PCR, 1 μg of total RNA was used as a template and 
reverse transcribed using Superscript II Reverse Transcriptase and 300 ng random 
primers as per the manufacturer’s instructions (Invitrogen, Carlsbad, CA). To perform 
semi-quantitative PCR, samples were amplified using 2 μL or RT reaction and primers 
specific to NME3 or GAPDH. PCR cycling conditions were: 95°C for 5 minutes, 35 
cycles (or 25 cycles for GAPDH reactions) of denaturation at 95°C for 45 seconds, 
annealing at 55°C for 45 seconds and extension at 72°C for 1 minute. PCR products were 
fractionated on a 1% agarose gel.  
 
4.4 Results  
To study IKK-induced activation of NF- κB by Salmonella in real time in living cells, we 
utilized a bioluminescent κB5→IκBα-FLuc fusion reporter.  This reporter consists of the 
negative inhibitor of NF-κB, IκBα, directly fused to firefly luciferase.  When the 
upstream kinase, IKK, is activated, it phosphorylates IκBα proteins in the host cell, 
targeting them for ubiquitination and proteasomal degradation.  In this case the reporter 
fusion protein serves as a direct readout of IKK activity [7].  As activated IKK 
phosphorylates IκBα, the reporter fusion is phosphorylated, ubiquitinated, and targeted 
for degradation as well.  This results in a reduction in bioluminescent reporter activity 
that can be followed in real time [7].  Liberation of NF-κB from its inhibitor frees it to 
translocate to the nucleus and activate transcription at NF-κB response elements.  The 
reporter fusion is linked on its 5’ end to five of these response elements in tandem, 
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allowing it to report on NF-κB nuclear transactivation ability as well by measuring an 
increase in bioluminescent signal [7].   Stimulation of HCT116 cells with heat-killed 
Salmonella robustly activates degradation and resynthesis of the reporter fusion, which 
can be imaged periodically to visualize the changes in reporter photon output following 
stimulation (Figure 4-1a).  Heat-killed bacteria were preferred as a stimulus over live 
bacteria. When performing the assay with live Salmonella, replication by the bacteria 
quickly changed the media conditions, ultimately leading to complete attenuation of the 
luciferase signal (data not shown).  The data obtained from imaging HCT116 cells 
stimulated with heat-killed Salmonella can also be represented graphically to demonstrate 
the dynamics of the reporter in the system (Figure 4-1b).  After stimulation with bacteria, 
the reporter signal initially decreased to 60% of its steady state level prior to activation.  
Following this decrease, which corresponds to IκBα degradation, the Salmonella-induced 
reporter activity rebounds to greater than three times the original bioluminescence levels, 
corresponding to transcriptional activation of the IκBα-FLuc fusion protein.  In 
comparison, TNFα, a common stimulus of NF-κB signaling, elicits more degradation and 
less transcriptional activation of the reporter.  Additionally, the dynamics of the HCT116 
cellular response to TNFα differ from those observed when HCT116 cells respond to 
Salmonella.  The peaks of reporter degradation and resynthesis both occur earlier 
following stimulation with TNFα, indicating differences in the signal transduction 
following the different stimuli. 
To understand how the HCT116 colon cancer cells are recognizing Salmonella and 
activating pro-inflammatory signaling, we set out to isolate the specific NF-κB -
activating moiety of the bacteria.  To accomplish this, we tested the NF-κB stimulatory 
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activity of individual known immunostimulatory components of bacteria.  When tested in 
HCT116 cells stably expressing the κB5→IκBα-FLuc reporter, purified peptidoglycan, 
NOD ligands (ieDAP and MDP), and bacterial LPS were all incapable of inducing 
significant bioluminescent reporter activity changes (Figure 4-2a-c).    Because bacterial 
flagellin is noted for its immunostimulatory activity, we chose to investigate its 
contribution to NF-κB activation by Salmonella.  To better determine the contribution of 
the two Salmonella flagellin proteins to NF-κB stimulation, we constructed Salmonella 
strains mutated singly or in both flagellin genes fliC and fljB.  Both single mutants were 
still able to activate NF-κB signaling, albeit to a lesser extent than that of wild type 
bacteria, but the Salmonella double mutant was incapable of activating NF-κB signaling 
in HCT116 cells.  This indicated that flagellin was the predominant ligand inducing NF-
κB signaling in HCT116 colon carcinoma cells (Figure 4-3).  Further, purified 
Salmonella flagellin also activates NF-κB signaling in this system although to a lesser 
extent than heat-killed Salmonella (data not shown). This may reflect a difference in the 
amount of flagellin produced by bacteria compared to the concentration of purified 
flagellin used, a difference in solubility between bacterially-produced and purified 
recombinant flagellin, or a difference in the relative amounts of monomeric versus 
polymerized flagellin in the two preparations.  Alternatively, perhaps heat-killed bacteria 
provide an additional co-activating ligand, in which case flagellin is necessary, but not 
sufficient to fully induce NF-κB signaling.   
With the knowledge that HCT116 cells are robustly activating proinflammatory signaling 
in response to Salmonella flagellin, we set out to identify novel host kinases involved in 
immunodetection of Salmonella. We utilized an siRNA screen to all known and predicted 
115 
 
human kinases to test the involvement of each in Salmonella-induced activation of NF-
κB.  The screen consisted of utilizing HCT116 cells colon carcinoma cells stably 
expressing the κB5→IκBα-FLuc construct. Cells were plated and transfected with siRNA 
targeting 691 host kinases arrayed in the 10 center columns of 96-well plates with each 
well containing two sequences targeting a single host kinase.  Forty-eight hours following 
siRNA transfection, cells were stimulated with heat-killed Salmonella and the reporter 
signal was measured immediately, at 45 minutes and at 245 minutes following the onset 
of Salmonella exposure (Figure 4-4).  Normalized bioluminescence signal data at 45 and 
245 minutes were plotted individually (Figure 4-5), or as x-y coordinates being the 
normalized signals at 45 and 245 minutes respectively (Figure 4-6).   
High-throughput screening hits were determined using a quartile-based analysis.  Figure 
4-5 displays the quartile-identified values for low- and high-stringency hit selection.  
Wells in which kinases that positively affect NF-κB signaling targeted by siRNA will 
demonstrate reduced responsiveness to Salmonella.  In contrast, wells containing siRNA 
targeting a negative regulator of NF-κB signaling will show enhanced reporter response.   
Statistically significant hits and their predicted regulatory activity on NF-κB signaling are 
listed in Table 4-1.  Figure 4-6 demonstrates the four possible effects kinases in the 
screen may have had on reporter activity.  Kinase knockdowns reducing the photon flux 
signal at 45 minutes, i.e., increasing IκBα degradation, indicate a negative regulator of 
NF-κB signaling has been targeted.   Meanwhile, kinase knockdowns with relatively 
greater photon flux signals at 45 minutes indicate siRNA targeted a positive regulator of 
NF-κB signaling.  Conversely, at the 245 minute time point smaller values represent a 
low signal during the resynthesis phase, which indicates a lack of full NF-κB 
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transactivation and therefore siRNA knockdown of a positive regulator of NF-κB induced 
transcription.  Greater photon flux values correspond to over-activation of NF-κB 
transcriptional activity, and therefore siRNA treatment targeted a negative transcriptional 
regulator.  Therefore, in Figure 4-6, an siRNA that acts on a positive regulator of both 
the degradation and resynthesis phases will fall in the lower right quadrant, while a 
negative regulator of both phases will be found in the upper left portion of the scatter 
plot.  The positive control well containing siRNA targeting TLR5, for example, should 
prevent IκBα degradation at 45 minutes, which in turn, will inhibit reporter 
transcriptional activation at 245 minutes.  This is shown by the blue triangle 
corresponding to TLR5 siRNA-treated wells falls in the lower right quadrant of the 
scatter plot.  IRAK1 and AKT, both known activators of the NF-κB signaling pathway, 
were identified as hits in the screen, further verifying the validity of the results.  The 
screen also identified MAP2K2 and MAP2K3, among others, as kinases involved in 
regulating the pathway. 
In the screen, knockdown of NME3 caused reduced transcriptional activation by NF-κB 
at 245 minutes, indicating NME3 was behaving as a positive regulator of NF-κB (Figure 
4-6).  Knockdown of NME3 by four individual siRNA sequences recapitulated the data in 
the primary screen, although sequence 3 shows less inhibition of NF-κB signaling, likely 
due to incomplete knockdown of NME3  (Figure 4-7).  Conversely, over-expression of 
plasmid-encoded NME3 in HCT116 cells induced higher levels of transcriptional 
activation by NF-κB, demonstrating that NME3 behaves as a positive regulator of NF-κB 
signaling in conditions of over-expression as well as under-expression (Figure 4-8).   
117 
 
To better measure the contribution of NME3 in Salmonella-induced activation of NF-κB, 
we constructed stable knockdowns of NME3 in HCT116 cells using shRNA lentiviral 
constructs.  Knockdown of NME3 by shRNA in wildtype HCT116 cells did indeed 
interfere with NF-κB signaling pathways (Figure 4-9a).  Compared to cells expressing a 
scrambled shRNA sequence, cells expressing shRNA targeted to NME3 show slightly 
less reporter degradation and much less resynthesis of the reporter during the 
transcriptional activation phase.   The responsiveness of a purely transcriptional reporter 
fusion was also tested in these cell lines.  As seen in NME3 knockdown cells expressing 
the κB5IκBαFLuc reporter, cells expressing a κB5FLuc construct show considerably 
less NF-κB-driven transcriptional activation following Salmonella stimulation (Figure 4-
9b).   Finally, semi-quantitative PCR confirms that NME3 mRNA in targeted shRNA-
expressing cells is indeed reduced to much lower levels compared to cells containing a 
non-targeting shRNA construct (Figure 4-9c). 
4.5 Discussion 
The NF-κB pathway specifically relies on kinases to effectively transmit signals from the 
extracellular space into activation of transcription in the nucleus.  Kinases, which 
phosphorylate other proteins, often have an activating role in a signal transduction 
pathway, and this holds true for the NF-κB signaling pathway as well.   For instance, the 
IκB kinase IKK, is rapidly phosphorylated in response to innate immune stimuli and 
downstream signaling requires such IKK activation.  The mechanism of IKK 
phosphorylation is not fully understood, but multiple kinases have been proposed, 
including RIP, TAK1, MAP3K14 and MAP3K1 as well as IKK itself through 
autophosphorylation [8].  Perhaps each of these kinases has a distinct role in IKK 
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activation.  As there are multiple upstream stimuli capable of activating IKK, i.e., TNFα, 
LPS, flagellin, multiple kinases likely exist to transmit these signals.  NF-κB can also be 
directly phosphorylated [9].  Cyclic AMP-dependent protein kinase (PKA) 
phosphorylates the p65 subunit of NF-κB on a specific serine residue, which activates 
transcriptional activity of NF-κB by enhancing DNA binding and aiding in transcriptional 
co-activator recruitment [9].    
Although not all kinases previously implicated in NF-κB signaling appeared to modulate 
the NF-κB signaling pathway in this high-throughput screen, multiple kinases that have 
been linked to the pathway did affect reporter activity in the screen.  Notably, IRAK1, a 
kinase with a central involvement to TLR signal transduction, is revealed in the screen as 
a positive regulator at 45 minutes and this correlates with its known role in IKK 
activation [10].   At 245 minutes, AKT is identified by the screen as a positive regulator 
of NF-κB, and indeed, Akt has been shown to play a role in full NF-κB activation and to 
promote nuclear NF-κB transactivation [11, 12].  Still, numerous kinases with well-
accepted important functions in the NF-κB pathway did not appear as hits in the high-
throughput screen.  In the cases of these kinases, such as IKKβ, there are several possible 
reasons for lack of detection.  First, the specific kinase may be expressed in such high 
levels, that siRNA knockdown is insufficient to reduce the protein levels enough to affect 
signaling.  Alternatively, if loss of a specific kinase is toxic the host cell may have 
compensating pathways to cope with loss of the kinase, thus preventing any phenotypic 
change.   Third, not all physiologically important kinases necessarily appear as high 
stringency hits in published screens, revealing the complexity of systems and their 
regulation. 
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Interestingly, one hit uncovered by the high-throughput siRNA screen was the kinase 
PTK6.  PTK6 is a tyrosine kinase linked to over-expression in multiple tumor types[13, 
14].  Recent research has demonstrated that plasma membrane-localized PTK6 enhances 
cellular proliferation, survival and migration – all downstream effects of NF-κB 
transcriptional activation[13].  Additionally, research has linked PTK6 to AKT activation 
through ERBB3, all kinases identified in the screen as positive regulators of NF-κB 
signaling.  In this work, EGF signaling to AKT was enhanced by PTK6 overexpression 
and mediated by ERBB3[15].  TLRs also have been shown to activate EGFR[16].  
Perhaps, in this case, TLR may be activating EGFR, which in turn transmits the 
proinflammatory signals downstream through PTK6, ERBB3 and AKT.  This may 
indicate a novel mechanism by which TLR5 may activate NF-κB signaling.   
Although siRNA-mediated knockdown of both MAP2K2 and MAP2K3 gave 
reproducible modulation of NF-κB, targeting known downstream MAP kinases via 
chemical inhibitor showed no effect in my system (data not shown). This could be 
explained by the identified kinases acting on other downstream proteins, as opposed to 
their typical MAP kinase targets.  Additionally, recent work identified MAP kinases as 
important modulators of NF-κB-induced cytokine production in intestinal epithelial cells 
with constitutively active NF-κB [17].    Because intestinal cancers often display high 
levels of active NF-κB, MAPK activation in these cells may be required for full 
inflammatory-mediated NF-κB transcriptional activation [18].  Perhaps this effect is the 
underlying reason for the seemingly important contribution of MAP2K2 and MAP2K3 in 
HCT116 colon carcinoma cells seen here.   
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Targeted siRNA sequences to the nucleotide diphosphate kinase NME3 had a drastic 
effect on NF-κB activation.  NME3 is one of eight human nucleotide diphosphate kinase 
genes [19].  These genes are capable of utilizing ATP to form non-ATP NTPs through 
their catalytic kinase domain, but have also been attributed with a large variety of 
potential functions from apoptosis regulation to cell migration to transcriptional 
activation [20].  Two homologues of NME3, NME1 and NME2, have been studied in 
much more detail than NME3 [20].  NME2 has demonstrated transcriptional activation of 
cMyc, a noted oncogene [21].  NME3 shows about 65% homology with NME2, and has 
an additional 17 amino acid N-terminal tail [20, 22].  NME3 has also been shown to 
activate integrin expression and adhesion characteristics– a known downstream target of 
NF-κB [23].  Perhaps, like NME2, NME3 acts as a transcription factor, and potentiates 
the action of NF-κB.  Follow-up analysis on NME3 would likely include investigating the 
role of NME3 in co-activating NF-κB-dependent transcription downstream of other 
stimuli, such as TNFα or IL-1β.  Also, DNA-binding studies may help clarify whether 
NME3 binds DNA to help co-activate transcription, similar to its homolog, NME2.   
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4.6 Tables 
Table 4-1 Kinases Modulating the NF-κB Pathway 
Gene 
name Gene function 
NF-κB 
regulatory 
activity, 45 
min α=0.1 
NF-κB 
regulatory 
activity, 45 
min α=0.02 
NF-κB 
regulatory 
activity, 245 
min α=0.1 
NF-κB 
regulatory 
activity, 245 
min α=0.02 
ACVR1 activin A receptor, type I NS NS NEGATIVE NS 
ACVR1B activin A receptor, type IB NS NS NEGATIVE NS 
ADRBK2 adrenergic, beta, receptor kinase 2 NEGATIVE NS NS NS 
AK5 adenylate kinase 5 NEGATIVE NS NS NS 
AKAP3 A kinase (PRKA) anchor protein 3 NEGATIVE NS NS NS 
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 NS NS NEGATIVE NS 
AKT1 v-akt murine thymoma viral oncogene homolog 1 NS NS POSITIVE POSITIVE 
ALPK2 alpha-kinase 2 POSITIVE POSITIVE NS NS 
ALS2CR7 amyotrophic lateral sclerosis 2 (juvenile) 
chromosome region, candidate 7 
POSITIVE NS NS NS 
APEG1 aortic preferentially expressed protein 1 NEGATIVE NS NS NS 
ARK5 AMP-activated protein kinase family member 5 NEGATIVE NS NS NS 
BLK B lymphoid tyrosine kinase POSITIVE POSITIVE NS NS 
BMX BMX non-receptor tyrosine kinase NS NS NEGATIVE NEGATIVE 
BTK Bruton agammaglobulinemia tyrosine kinase NS NS NEGATIVE NEGATIVE 
CALM3 calmodulin 3 (phosphorylase kinase, delta) POSITIVE NS NS NS 
CAMK2B calcium/calmodulin-dependent protein kinase 
(CaM kinase) II beta 
NS NS NEGATIVE NS 
CAMK2G calcium/calmodulin-dependent protein kinase 
(CaM kinase) II gamma 
NEGATIVE NS NS NS 
CAMK4 calcium/calmodulin-dependent protein kinase IV POSITIVE POSITIVE NS NS 
122 
 
CCRK cell cycle related kinase POSITIVE NS POSITIVE POSITIVE 
CaMKIINalp
ha 
calcium/calmodulin-dependent protein kinase II POSITIVE NS POSITIVE NS 
CDK10 cyclin-dependent kinase (CDC2-like) 10 POSITIVE POSITIVE NS NS 
CDK3 cyclin-dependent kinase 3 NEGATIVE NS NS NS 
CDK4 cyclin-dependent kinase 4 NS NS NEGATIVE NS 
CDK5R2 cyclin-dependent kinase 5, regulatory subunit 2 
(p39) 
NEGATIVE NEGATIVE NS NS 
CDK6 cyclin-dependent kinase 6 NS NS NEGATIVE NEGATIVE 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) NS NS POSITIVE NS 
CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
POSITIVE NS NS NS 
CKB creatine kinase, brain NS NS NEGATIVE NS 
CKMT1 creatine kinase, mitochondrial 1 (ubiquitous) NS NS NEGATIVE NS 
CNKSR1 connector enhancer of kinase suppressor of Ras 1 NEGATIVE NS NS NS 
CSK c-src tyrosine kinase POSITIVE NS NS NS 
CSNK1A1 casein kinase 1, alpha 1 POSITIVE NS NS NS 
CSNK1D casein kinase 1, delta NS NS NEGATIVE NEGATIVE 
CSNK1G2 casein kinase 1, gamma 2 NS NS NEGATIVE NEGATIVE 
CSNK2A1 casein kinase 2, alpha 1 polypeptide NS NS NEGATIVE NS 
CSNK2A2 casein kinase 2, alpha prime polypeptide POSITIVE NS NS NS 
DGKA diacylglycerol kinase, alpha 80kDa NS NS NEGATIVE NS 
DGKB diacylglycerol kinase, beta 90kDa POSITIVE NS NS NS 
DGKE diacylglycerol kinase, epsilon 64kDa NS NS NEGATIVE NS 
DGKQ diacylglycerol kinase, theta 110kDa NS NS POSITIVE NS 
DGUOK deoxyguanosine kinase POSITIVE POSITIVE NS NS 
DMPK dystrophia myotonica-protein kinase NS NS NEGATIVE NEGATIVE 
EGFR epidermal growth factor receptor (erythroblastic NEGATIVE NS NS NS 
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leukemia viral (v-erb-b) oncogene homolog, 
avian) 
EPHA1 EPH receptor A1 NEGATIVE NS POSITIVE NS 
EPHA2 EPH receptor A2 NS NS POSITIVE NS 
EPHA3 EPH receptor A3 POSITIVE POSITIVE NS NS 
EPHA4 EPH receptor A4 POSITIVE NS NS NS 
EPHA5 EPH receptor A5 POSITIVE NS NS NS 
EPHA7 EPH receptor A7 NEGATIVE NS NS NS 
EPHA8 EPH receptor A8 NS NS POSITIVE NS 
EPHB2 EPH receptor B2 POSITIVE POSITIVE POSITIVE POSITIVE 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3 (avian) 
POSITIVE POSITIVE NS NS 
ERN2 endoplasmic reticulum to nucleus signalling 2 NS NS NEGATIVE NS 
FASTK FAST kinase NS NS POSITIVE NS 
FER fer (fps/fes related) tyrosine kinase 
(phosphoprotein NCP94) 
POSITIVE NS POSITIVE NS 
FES feline sarcoma oncogene NS NS NEGATIVE NS 
FGFR2 fibroblast growth factor receptor 2 (bacteria-
expressed kinase, keratinocyte growth factor 
receptor, craniofacial dysostosis 1, Crouzon 
syndrome, Pfeiffer syndrome, Jackson-Weiss 
syndrome) 
POSITIVE POSITIVE POSITIVE NS 
FGFR4 fibroblast growth factor receptor 4 NS NS NEGATIVE NS 
FLT3LG fms-related tyrosine kinase 3 ligand NEGATIVE NS NS NS 
GK glycerol kinase NS NS NEGATIVE NS 
GK2 glycerol kinase 2 NS NS POSITIVE NS 
GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase 
NEGATIVE NS NS NS 
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GRK5 G protein-coupled receptor kinase 5 NEGATIVE NS NS NS 
GSK3A glycogen synthase kinase 3 alpha POSITIVE POSITIVE POSITIVE POSITIVE 
GSK3B glycogen synthase kinase 3 beta NS NS NEGATIVE NS 
HK1 hexokinase 1 NS NS NEGATIVE NS 
HUNK hormonally upregulated Neu-associated kinase POSITIVE NS NS NS 
IHPK3 inositol hexaphosphate kinase 3 POSITIVE POSITIVE NS NS 
IKBKAP inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase complex-associated 
protein 
NS NS POSITIVE POSITIVE 
IRAK1 interleukin-1 receptor-associated kinase 1 POSITIVE POSITIVE NS NS 
IRAK2 interleukin-1 receptor-associated kinase 2 POSITIVE NS NS NS 
ITK IL2-inducible T-cell kinase NEGATIVE NS NS NS 
ITPKA inositol 1,4,5-trisphosphate 3-kinase A POSITIVE POSITIVE NS NS 
KDR kinase insert domain receptor (a type III receptor 
tyrosine kinase) 
POSITIVE POSITIVE NS NS 
KHK ketohexokinase (fructokinase) NS NS NEGATIVE NS 
LCK lymphocyte-specific protein tyrosine kinase POSITIVE POSITIVE NS NS 
LOC375449 similar to microtubule associated testis specific 
serine/threonine protein kinase 
NS NS NEGATIVE NS 
LOC400301 similar to protein kinase CHK2 isoform b; 
checkpoint-like protein CHK2; serine/threonine-
protein kinase CHK2; CHK2 (checkpoint, S.pombe) 
homolog 
NEGATIVE NS NS NS 
LRRK2 leucine-rich repeat kinase 2 POSITIVE NS NS NS 
LTK leukocyte tyrosine kinase POSITIVE NS NS NS 
LYN v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog 
POSITIVE NS NS NS 
MAP2K2 mitogen-activated protein kinase kinase 2 POSITIVE POSITIVE POSITIVE POSITIVE 
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MAP2K3 mitogen-activated protein kinase kinase 3 POSITIVE POSITIVE POSITIVE POSITIVE 
MAP2K6 mitogen-activated protein kinase kinase 6 POSITIVE NS NS NS 
MAP2K7 mitogen-activated protein kinase kinase 7 NEGATIVE NS NS NS 
MOS v-mos Moloney murine sarcoma viral oncogene 
homolog 
POSITIVE NS NS NS 
MAP3K12 mitogen-activated protein kinase kinase kinase 12 NS NS POSITIVE NS 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 POSITIVE NS NS NS 
MAPK10 mitogen-activated protein kinase 10 NS NS POSITIVE NS 
MAPK14 mitogen-activated protein kinase 14 POSITIVE NS NEGATIVE NEGATIVE 
MAPK6 mitogen-activated protein kinase 6 NS NS POSITIVE POSITIVE 
MAPK7 mitogen-activated protein kinase 7 NS NS POSITIVE NS 
MAPKAP1 mitogen-activated protein kinase associated 
protein 1 
NS NS POSITIVE NS 
MAPKBP1 mouse mitogen-activated protein kinase binding 
protein 1-like 
NS NS POSITIVE NS 
MET met proto-oncogene (hepatocyte growth factor 
receptor) 
POSITIVE NS NS NS 
MGC40579 hypothetical protein MGC40579 POSITIVE POSITIVE NS NS 
NEK1 NIMA (never in mitosis gene a)-related kinase 1 POSITIVE NS NS NS 
NEK2 NIMA (never in mitosis gene a)-related kinase 2 NS NS NEGATIVE NS 
NEK3 NIMA (never in mitosis gene a)-related kinase 3 NS NS POSITIVE NS 
NEK8 NIMA (never in mitosis gene a)- related kinase 8 POSITIVE NS NS NS 
NME2 non-metastatic cells 2, protein (NM23B) 
expressed in 
POSITIVE NS NS NS 
NME3 non-metastatic cells 3, protein expressed in NS NS POSITIVE POSITIVE 
PACSIN2 protein kinase C and casein kinase substrate in 
neurons 2 
NEGATIVE NS NS NS 
PANK2 pantothenate kinase 2 (Hallervorden-Spatz NS NS POSITIVE NS 
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syndrome) 
PBK PDZ binding kinase POSITIVE POSITIVE POSITIVE POSITIVE 
PCTK3 PCTAIRE protein kinase 3 NS NS POSITIVE POSITIVE 
PDGFRA platelet-derived growth factor receptor, alpha 
polypeptide 
NS NS NS NS 
PDGFRB platelet-derived growth factor receptor, beta 
polypeptide 
NS NS NEGATIVE NS 
PDK1 pyruvate dehydrogenase kinase, isoenzyme 1 NEGATIVE NEGATIVE NEGATIVE NS 
PDK2 pyruvate dehydrogenase kinase, isoenzyme 2 POSITIVE POSITIVE NS NS 
PDK3 pyruvate dehydrogenase kinase, isoenzyme 3 NEGATIVE NS NEGATIVE NS 
PDLIM5 PDZ and LIM domain 5 NEGATIVE NS NS NS 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2 
POSITIVE NS NS NS 
PHKA1 phosphorylase kinase, alpha 1 (muscle) NS NS NEGATIVE NS 
PHKG1 phosphorylase kinase, gamma 1 (muscle) POSITIVE NS NS NS 
PIK3CD phosphoinositide-3-kinase, catalytic, delta 
polypeptide 
POSITIVE POSITIVE POSITIVE POSITIVE 
PIK3CG phosphoinositide-3-kinase, catalytic, gamma 
polypeptide 
NS NS POSITIVE POSITIVE 
PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 
(p85 beta) 
NEGATIVE NS NS NS 
PIK3R4 phosphoinositide-3-kinase, regulatory subunit 4, 
p150 
NS NS NEGATIVE NS 
PIK4CB phosphatidylinositol 4-kinase, catalytic, beta 
polypeptide 
POSITIVE POSITIVE NS NS 
PIM1 pim-1 oncogene NEGATIVE NEGATIVE NS NS 
PIM2 pim-2 oncogene NS NS NEGATIVE NS 
PKN2 protein kinase N2 POSITIVE POSITIVE NS NS 
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PKN3 protein kinase N3 NS NS POSITIVE NS 
PLK1 polo-like kinase 1 (Drosophila) POSITIVE NS POSITIVE NS 
PRKAG1 protein kinase, AMP-activated, gamma 1 non-
catalytic subunit 
NEGATIVE NS NS NS 
PRKAR1B protein kinase, cAMP-dependent, regulatory, 
type I, beta 
NEGATIVE NS NS NS 
PRKAR2A protein kinase, cAMP-dependent, regulatory, 
type II, alpha 
NEGATIVE NEGATIVE POSITIVE NS 
PRKAR2B protein kinase, cAMP-dependent, regulatory, 
type II, beta 
NEGATIVE NS NS NS 
PRKCABP protein kinase C, alpha binding protein NEGATIVE NS NS NS 
PRKCDBP protein kinase C, delta binding protein NS NS POSITIVE NS 
PRKD1 protein kinase D1 POSITIVE NS POSITIVE NS 
PRKG2 protein kinase, cGMP-dependent, type II NS NS POSITIVE NS 
PRKX protein kinase, X-linked NS NS POSITIVE NS 
PRKY protein kinase, Y-linked NS NS POSITIVE NS 
PSKH1 protein serine kinase H1 NS NS NEGATIVE NS 
PTK6 PTK6 protein tyrosine kinase 6 POSITIVE NS NS NS 
RAF1 v-raf-1 murine leukemia viral oncogene homolog 
1 
NEGATIVE NS NS NS 
RPS6KA1 ribosomal protein S6 kinase, 90kDa, polypeptide 
1 
POSITIVE NS NS NS 
DCAMKL1 doublecortin and CaM kinase-like 1 NEGATIVE NEGATIVE NS NS 
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 
1 
NS NS NEGATIVE NS 
RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 
2 
POSITIVE NS NS NS 
RPS6KL1 ribosomal protein S6 kinase-like 1 POSITIVE NS NS NS 
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RYK RYK receptor-like tyrosine kinase NS NS POSITIVE NS 
SNF1LK SNF1-like kinase NS NS NEGATIVE NS 
STK22D serine/threonine kinase 22D (spermiogenesis 
associated) 
POSITIVE POSITIVE POSITIVE NS 
STK25 serine/threonine kinase 25 (STE20 homolog, 
yeast) 
POSITIVE NS NS NS 
STK32C serine/threonine kinase 32C NS NS NEGATIVE NS 
STK11 serine/threonine kinase 11 (Peutz-Jeghers 
syndrome) 
POSITIVE NS NS NS 
TAOK1 TAO kinase 1 NS NS POSITIVE NS 
TEK TEK tyrosine kinase, endothelial (venous 
malformations, multiple cutaneous and mucosal) 
NEGATIVE NS NS NS 
TESK1 testis-specific kinase 1 POSITIVE POSITIVE POSITIVE NS 
TGFBR2 transforming growth factor, beta receptor II 
(70/80kDa) 
NEGATIVE NEGATIVE POSITIVE POSITIVE 
TIE1 tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1 
NEGATIVE NS NS NS 
TNK2 tyrosine kinase, non-receptor, 2 NEGATIVE NS NS NS 
TYRO3 TYRO3 protein tyrosine kinase NEGATIVE NEGATIVE NS NS 
ULK2 unc-51-like kinase 2 (C. elegans) NEGATIVE NS NS NS 
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4.7 Figures 
 
Figure 4-1 
 
 
Figure 4-1: Real-time activation of NF-κB signaling by Salmonella Typhimurium.  
HCT116 cells transiently transfected with pκB5IκBαFLuc were stimulated with heat-
killed Salmonella at T=0 and imaged for reporter activity every 5 minutes for 6 hours. (a) 
Photon flux images obtained every 20 minutes are shown.  (b) Data are displayed as the 
fold-initial photon flux values.  Imaging parameters: acquisition time, 60 sec; binning, 4; 
filter, open; f stop, 1; FOV, 23 cm.   
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Figure 4-2 
 
 
 
 
Figure 4-2: LPS, Peptidoglycan and NOD ligands do not significantly contribute to 
NF-κB activation in HCT116 cells in response to Salmonella.  HCT116 cells stably 
expressing κB5IκBαFLuc were stimulated with the indicated ligand at T=0 and imaged 
for reporter activity every 5 minutes for 6 hours.  Data is displayed as normalized photon 
flux values (Fold-initial, fold-vehicle).  Imaging parameters: acquisition time, 60 sec; 
binning, 8; filter, open; f stop, 1; FOV, 20 cm(a,c) 15 cm(b).   
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Figure 4-3 
 
 
 
Figure 4-3: Salmonella flagellin activates NF-κB signaling in HCT116 colon 
carcinoma cells.  HCT116 cells stably expressing κB5IκBαFLuc were stimulated with 
heat-killed wild-type Salmonella, fliC-, fjB-, or fliC-/fjB- at T=0 and imaged for reporter 
activity every 5 minutes for 6 hours.  Data is displayed as normalized photon flux values 
(Fold-initial, fold-vehicle).  Imaging parameters: acquisition time, 60 sec; binning, 8; 
filter, open; f stop, 1; FOV, 20 cm. 
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Figure 4-4 
 
 
 
Figure 4-4: A schematic of the high-throughput screening technique.  (a)HCT116 
cells stably expressing κB5IκBαFLuc were plated into 96-well plates.  After a 24-hour 
incubation, cells were transfected with siRNA and incubated for 48 hours more.  To 
image, cells were transferred into d-luciferin-containing media, allowed to equilibrate for 
45 minutes, stimulated with heat-killed Salmonella and imaged for reporter activity at 0, 
45 and 245 minutes.  (b) Each siRNA library plate contained targeting siRNA in columns 
2-11 and control siRNA constructs in columns 1 and 12, as indicated.  Control wells 
included: mock-transfected cells (blue, A1), vehicle-treated wells (yellow; E1, F1, G1, 
H1), three non-targeting control sequences (turquoise, Qiagen Allstar Negative control, 
133 
 
F12; Qiagen scrambled siRNA, G12; Qiagen GFP siRNA, H12), TLR5-targetting siRNA 
sequences (red, IDT, C1, C12, D1, D12), and a firefly luciferase-targeting PGL3 siRNA 
(purple, Dharmacon Research Inc, A12, B12).   
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Figure 4-5 
 
 
Figure 4-5: High-throughput screening data.  Normalized photon flux data for 691 
targeted kinases is shown at 45(a) and 245(b) minutes after Salmonella situation.  Data is 
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the average of three replicates.  Dotted blue and dashed red lines show significance cut-
offs for low (α = 0.1) and high (α = 0.02) stringency targeted error rates, respectively.   
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Figure 4-6 
 
a 
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Figure 4-6:  MAP2K2, MAP2K3 and NME3 act as positive regulators of Salmonella-
induced NF-κB pathways.  (a) A schematic diagram shows the proposed regulatory 
activity on NF-κB by kinase targets in each of four quadrants in the plot. (b) The 
normalized photon flux data from the primary screen at 45 minutes and 245 minutes are 
plotted on the x- and y- axes, respectively.  Highlighted points show data from specific 
screening hits and TLR5 control wells.   
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Figure 4-7 
 
 
Figure 4-7:  NME3 knockdown inhibits NF-κB. HCT116 cells stably expressing 
κB5IκBαFLuc and transfected with the indicated siRNA constructs were stimulated 
with heat-killed Salmonella and imaged for reporter activity every 5 minutes for 6 hours.  
Data is displayed as normalized photon flux values (fold-initial, fold-untreated).  
Individual siRNA sequences targeting NME3 show reduced IκBαFLuc reporter 
responsiveness.  Imaging parameters: acquisition time, 60 sec; binning, 8; filter, open; f 
stop, 1; FOV, 12 cm. 
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Figure 4-8 
 
Figure 4-8:  NME3 over-expression induces NF-κB transcriptional activation. 
HCT116 cells were transfected with pκB5IκBαFLuc and the indicated plasmid 
constructs and stimulated with heat-killed Salmonella and imaged for reporter activity 
every 5 minutes for 6 hours.  Data is displayed as normalized photon flux values (fold-
initial, fold-untreated).  Plasmid-based over-expression of NME3 induces over-
expression of NF-κB transcriptional targets.  Imaging parameters: acquisition time, 60 
sec; binning, 8; filter, open; f stop, 1; FOV, 12 cm. 
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Figure 4-9 
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Figure 4-9:  Targeting NME3 by shRNA reduces NF-κB responsiveness. (a) HCT116 
cells were subjected to lentiviral knockdown with the indicated shRNA constructs and 
transfected with the pκB5IκBαFLuc plasmid.  Cells were then stimulated with heat-
killed Salmonella and imaged for reporter activity every 5 minutes for 6 hours.  Data is 
displayed as normalized photon flux values (fold-initial, fold-untreated).  Imaging 
parameters: acquisition time, 30 sec; binning, 8; filter, open; f stop, 1; FOV, 15 cm.  (b) 
HCT116 cells were subjected to lentiviral knockdown with the indicated shRNA 
constructs and transfected with the pκB5FLuc plasmid.  Imaging was performed at 0, 
2, 4, 6, and 7 hours following stimulation with Salmonella.  Data is displayed as 
normalized photon flux values (fold-initial, fold-untreated). IVIS 50 Imaging parameters: 
acquisition time, 10 sec; binning, 8; filter, open; f stop, 1; FOV, 12 cm.  (c) Semi-
quantitative PCR verifies knockdown of NME3 mRNA in shRNA-expressing HCT116 
cells.  GAPDH mRNA levels are shown as a control.   
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CHAPTER FIVE 
A High-Throughput siRNA Screen to Identify Novel 
Host Phosphatases Involved in Regulation of Salmonella 
Induction of Inflammation  
5.1 Introduction 
NF-κB is a key transcription factor and mediator of human innate immunity and stress-
response pathways.  The protein can be activated by a number of different stimulatory 
signals, including cytokines, microbial PAMPs and reactive oxygen species (ROS).  One 
major outcome of activated NF-κB signaling is the activation of genes involved in 
promoting cellular survival and inhibiting apoptosis.  Unregulated NF-κB signaling, 
therefore, can lead to increased levels of cellular proliferation and has been linked to 
cancer and other chronic inflammatory diseases [1].   
Phosphatases are key players in many host signal transduction pathways and are known 
to specifically modulate the NF-κB pathway at several instances.  For example, the 
phosphatase PP-2A acts to dephosphorylate IKKβ [2].  Also, WIP1 phosphatase acts to 
directly dephosphorylate an activating serine phosphorylation on the p65 subunit of NF-
κB, thereby inhibition NF-κB activity [3].   
Although other studies have identified novel phosphatase modulators of NF-κB signaling, 
these studies most often utilize TNFα as the NF-κB-stimulating ligand.  Yet, the NF-κB 
pathway is activated by multiple other stimuli that lead to different downstream signaling 
intermediates.  For example, many of the proteins directly downstream of TLR activation 
are not required for TNFα-induced signaling and different TLRs recruit different adapters 
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to transduce their signals.  Therefore, novel phosphatase actions may be discovered by 
studying the NF-κB pathway downstream of TLR signaling as well.    
To investigate the contribution of individual phosphatases to Salmonella-induced 
activation of NF-κB, I performed an siRNA screen.  By imaging the degradation and 
resynthesis of an NF-κB-driven IκBα-FLuc reporter, I could study the individual 
contributions of each phosphatase in two separate phases of NF-κB pathway activation.   
5.2 Methods 
Cell lines and culture conditions:  HCT116 cells were a gift of Bert Vogelstein and 
cultured according to ATCC directions.  All stably transfected HCT116 cells were 
cultured in 0.5 µg/ml puromycin.   
Salmonella strains: Salmonella Typhimurium strain SL1344 was used for all 
experiments.  
Creation of a κB5IκBαFLuc-expressing HCT116 stable cell line: HCT116 cells at 95% 
confluency were co-transfected with 10 µg of pκB5IκBαFLuc and 3 µg of pIRES-puro 
plasmid DNA using Fugene 6 in 10 cm dishes.  After 24 hours the media was replaced 
with fresh cell media.  Twenty-four hours later the cells were split at multiple dilutions 
into media containing 0.5µg/ml puromycin to select for stable transformants.  After two 
weeks, isolated cell colonies were imaged to check for reporter gene expression and 
bioluminescent colonies were harvested and expanded.  The HCT116 stable cells were 
continuously cultured in the presence of 0.5µg/ml puromycin to maintain expression of 
the reporter plasmid.  
High-throughput screen: siRNA screening was performed in white, clear-bottomed, 96-
well culture plates using a Beckman-Coulter Core robotics system, including an FX 
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liquid handler, controlled by the Sagian graphical method development tool (SAMI 
scheduling software).  HCT116 cells stably expressing pκB5IκBαFLuc were seeded at 
15,000 cells per well and allowed to attach for 24 hours.  Forward transfection was 
performed with a 96 multichannel head on the FX liquid handler, adding 0.5 µl/well of 
media-complexed R1 Transpass (NEB) to the aliquotted siRNA library (Kinase siRNA 
set v2; Qiagen Inc.) in a 96-well reaction plate and allowed to incubate for 15 minutes.  
Experimental siRNA oligos were arrayed in columns 2-11 of each plate and individual 
controls comprising vehicle-treated wells, a non-targeting control sequence (Qiagen 
Allstar Negative control), TLR5-targetting siRNA sequences (IDT), and a firefly 
luciferase-targeting PGL3 siRNA (Dharmacon Research Inc.) were placed manually in 
columns 1 and 12.  After incubation of siRNA complexes, 100 µl was added to each well 
of a plate with cells (x3 plates) using the FX liquid handler, yielding a final concentration 
of ~50 nM siRNA/well.  Plates were maintained at 37ºC and 5% CO2 for 48 hours.  At 
this time, media were aspirated and replaced with 180 µl imaging media (colorless 
DMEM supplemented with 10% heat inactivated FBS and 150 µg/ml d-luciferin) and the 
cells were allowed to equilibrate for 45 minutes.  After equilibrating, 20 µl of stimulus 
(1:100 dilutions of heat-killed Salmonella cultures) or control (LB broth) were added to 
each well.  Bioluminescent readings were obtained on an EnVision plate reader 
(PerkinElmer) immediately following stimulus, at 45 minutes post-stimulation and at 245 
minutes post-stimulation.  After the final luminescent reading, 20 µl of rezasurin dye was 
added to all wells, allowed to incubate for 2 hours at 37ºC and monitored on a FLUOstar 
OPTIMA fluorescence reader (BMG Labtech; excitation, 544 nm, emission, 590 nm).   
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Data analysis:  Initially, the signal in each well was normalized to a plate-matched 
control well containing a non-targeting siRNA sequence to facilitate experiment-wide 
analysis.  Then, the differences in the log2 values of the normalized data between 0 
minutes and 45 or 245 minutes were averaged across triplicate siRNA experimental 
replicates.  Screening hits were selected by quartile analysis of the normalized kinase 
library data.  To perform the quartile analysis, median (Q2), first (Q1) and third (Q3) 
quartile values were calculated.  From these values, the upper and lower boundaries for 
hit selection were calculated as Q3 + 2c(Q3 –Q2) and Q1 – 2c(Q2-Q1), respectively, for 
c = 0.9529 corresponding to a targeted error rate (α = 0.05).   
5.3 Results  
To identify novel host factors involved in Salmonella-induced activation of innate 
immunity, an siRNA screen targeting all known and predicted host phosphatases was 
performed in HCT116 colon carcinoma cells.  The HCT116 colon carcinoma cells were 
stably transfected with a plasmid containing five tandem NF-κB binding sites driving an 
IκBα-FLuc fusion reporter construct.  This reporter permitted imaging two separate 
stages in the activation of the NF-κB pathway.  The first stage is the early degradation of 
the fusion reporter, representing degradation of IκBα, the negative regulator NF-κB, 
which preceeds nuclear translocation NF-κB.  Then, the second stage represents the 
transcriptional activation mediated by NF-κB, which drives reporter synthesis, due to the 
five tandem NF-κB binding sites.  These two stages can be measured by an initial 
decrease in bioluminescence, followed by a large increase in bioluminescent signal, 
respectively.  HCT116 cells stably expressing this reporter were treated with siRNA 
constructs (2 sequences per well) targeting individual host phosphatases for 48 hours.  
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Then, heat-killed preparations for Salmonella were added to stimulate NF-κB signaling.  
The normalized data obtained from imaging at 45 minutes and 245 minutes are shown in 
Figures 5-1a and b.  Additionally, to combine the information acquired for each targeted 
phosphatase, the data can be plotted with the 45-minute signals on the x-axis and the 245 
minute signals on the y-axis (Figure 5-2).  In this plot, positive values along the x-axis 
correspond to phosphatase knockdowns that induced less reporter degradation than 
control, indicating phosphatases that positively modulate the degradation phase of NF-κB 
signaling.  Conversely negative x-values represent wells that induced more reporter 
degradation and therefore represent phosphatses with a negative regulatory role in NF-κB 
signaling.  At 245 minutes, represented by y-values, positive and negative values 
represent negative and positive regulators of NF-κB signaling, respectively.  In this case, 
data representing a phosphatase acting as a positive regulator of NF-κB signaling at both 
time points will fall in the lower right quadrant of the plot, as in the case of the TLR-5 
control siRNA.  A summary of all statistically significant hits and their predicted 
regulatory activity on NF-κB signaling are listed in Table 5-1.   
5.4 Discussion 
Salmonella is known to activate NF-κB signaling through activation of Toll-like 
receptors in host cells.  In order to identify potential novel phosphatases involved in 
Salmonella-induced activation of host NF-κB signaling through bacterial flagellin, we 
utilized a high-throughput siRNA screen.  Interestingly, phosphatases are often credited 
as negative regulatory proteins in signal transduction pathways, and the global high-
throughput screening data obtained here seem to confirm this role.  At both the 45 and 
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245 minute time points, the majority of assayed phosphatases are negatively regulating 
NF-κB signaling.   
Several of the phosphatases identified as hits in the high throughput screen belong to the 
PP2C family of phosphatases.  PPM1A, PPM1G, and PPM1L are all phosphatases in the 
PP2C family, a group of serine/threonine phosphatases found in eukaryotes that have 
been shown to have roles in negative regulation of stress responses [4, 5].  WIP1 
phosphatase also belongs to the PP2C family and has previously been shown to modulate 
NF-κB signaling, but was not a hit in this high-throughput screen [3].  However the 
experiments with WIP1 demonstrated its role in TNFα and IL-1β-induced signaling, and 
perhaps WIP1 is less relevant to TLR-induced NF-κB signaling as studied here [3].  
PPM1A has been shown to negatively regulate NF-κB signaling, and in previous work, 
knockdown of PPM1A induced enhanced NF-κB nuclear translocation and downstream 
gene activation, similar to the results in this high-throughput screen [4].  PPM1L and 
PPM1G have demonstrated opposing roles in regulation of cellular stress response 
pathways in previous work, verifying the data from this screen [5].  However, these 
studies have demonstrated negative regulation of TNFα-induced activation of MAP 
kinase and pro-apoptotic signaling by PPM1L and positive regulation by PPM1G, the 
opposite of the effects observed in this screen [5].  Because NF-κB activation by TNFα 
serves to prevent apoptosis, it could be reasoned that while PPM1L negatively regulates 
TNFα induction of apoptosis, it effectively positively regulates TNFα induction of NF-κB 
signaling, thereby creating roles for PPM1L and PPM1G in positive and negative 
regulation of NF-κB signaling, respectively, as demonstrated here [6].    
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Another phosphatase identified in the screen, PTPNS1, has also been shown to play an 
important role in AKT activation following treatment with TNFα or IL-1β [7].  Because 
AKT is likely involved in activation of NF-κB signaling, PTPNS1 may be required for 
full activation of NF-κB downstream of TLR signaling as well [8].  Finally, in a study of 
host lipid compounds called resolvins that regulate host inflammatory pathways, ALP1 
was linked to cellular resolution of inflammation [9].  In this work, resolvin treatment 
induce ALP1 expression, which reduced NF-κB activation and promoted resolution of 
inflammation[9].  However, the researchers in the study claim the anti-inflammatory role 
of ALP1 lies in its dephosphorylation of LPS, which detoxifies the bacterial product.  
However, based on the data from the high-throughput screen performed here, the role of 
ALP1seems more likely to be dephosphorylation of a common intermediate in TLR4 and 
TLR5 signal transduction.  It would be interesting to determine where ALP1 negatively 
regulates NF-κB activation downstream of cytokine receptors, such as TNFR, as well. 
The phosphatases identified here warrant further functional studies to better understand 
their roles in modulation of NF-κB.  ALP1 is of particular interest based on its 
hypothesized role as a mediator of resolution of inflammation.  Through further research 
on ALP1 we may discover new ways to target over-active inflammatory responses.   
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5.5 Tables  
 
Table 5-1 Phosphatases Modulating the NF-κB Pathway 
Gene name Gene function 
NF-κB 
regulatory 
activity, 45 
min α=0.1 
NF-κB 
regulatory 
activity, 45 
min α=0.02 
NF-κB 
regulatory 
activity, 245 
min α=0.1 
NF-κB 
regulatory 
activity, 245 
min α=0.02 
ALPI alkaline phosphatase, intestinal NEGATIVE NS NS NS 
CTDSP2 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 2 NS NS POSITIVE NS 
DOLPP1 dolichyl pyrophosphate phosphatase 1 POSITIVE POSITIVE NS NS 
DUSP12 dual specificity phosphatase 12 NS NS NEGATIVE NS 
DUSP7 dual specificity phosphatase 7 NS NS POSITIVE NS 
ENPP1 
ectonucleotide pyrophosphatase/phosphodiesterase 
1 NS NS NEGATIVE NS 
FBP1 fructose-1,6-bisphosphatase 1 NS NS NEGATIVE NEGATIVE 
G6PC 
glucose-6-phosphatase, catalytic (glycogen storage 
disease type I, von Gierke disease) NS NS NEGATIVE NS 
G6PC3 glucose 6 phosphatase, catalytic, 3 POSITIVE POSITIVE POSITIVE NS 
INPP5B inositol polyphosphate-5-phosphatase, 75kDa NS NS POSITIVE NS 
LHPP 
phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase POSITIVE POSITIVE NS NS 
LOC387870 
similar to protein tyrosine phosphatase, receptor 
type, Q isoform 1 precursor; glomerular mesangial 
cell receptor protein-tyrosine phosphatase; 
glomerular mesangial cell receptor protein-tyrosine 
phosphatase precursor NS NS POSITIVE POSITIVE 
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PHPT1 phosphohistidine phosphatase 1 POSITIVE POSITIVE POSITIVE NS 
PLIP PTEN-like phosphatase NS NS POSITIVE NS 
PNKP polynucleotide kinase 3'-phosphatase POSITIVE NS POSITIVE NS 
PPFIA4 
protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), 
alpha 4 POSITIVE NS NS NS 
PPM1A 
protein phosphatase 1A (formerly 2C), magnesium-
dependent, alpha isoform NS NS NEGATIVE NS 
PPM1G 
protein phosphatase 1G (formerly 2C), magnesium-
dependent, gamma isoform NS NS NEGATIVE NEGATIVE 
PPM1L protein phosphatase 1 (formerly 2C)-like POSITIVE NS POSITIVE NS 
PPP1CB 
protein phosphatase 1, catalytic subunit, beta 
isoform NS NS NEGATIVE NEGATIVE 
PPP1CC 
protein phosphatase 1, catalytic subunit, gamma 
isoform NS NS NEGATIVE NEGATIVE 
PPP1R12C 
protein phosphatase 1, regulatory (inhibitor) subunit 
12C POSITIVE POSITIVE NS NS 
PPP1R15B 
protein phosphatase 1, regulatory (inhibitor) subunit 
15B POSITIVE POSITIVE NS NS 
PPP1R2 
protein phosphatase 1, regulatory (inhibitor) subunit 
2 NEGATIVE NS NS NS 
PPP1R3B 
protein phosphatase 1, regulatory (inhibitor) subunit 
3B POSITIVE NS NS NS 
PPP1R3D protein phosphatase 1, regulatory subunit 3D NS NS NEGATIVE NS 
PPP1R3F 
protein phosphatase 1, regulatory (inhibitor) subunit 
3F NS NS NS NS 
PPP1R8 
protein phosphatase 1, regulatory (inhibitor) subunit 
8 NEGATIVE NS NEGATIVE NS 
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PPP2R2C 
protein phosphatase 2 (formerly 2A), regulatory 
subunit B (PR 52), gamma isoform NS NS NEGATIVE NEGATIVE 
PTPDC1 protein tyrosine phosphatase domain containing 1 POSITIVE POSITIVE POSITIVE POSITIVE 
PTPN22 
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) POSITIVE POSITIVE NS NS 
PTPNS1 
protein tyrosine phosphatase, non-receptor type 
substrate 1 POSITIVE POSITIVE POSITIVE POSITIVE 
PTPRB protein tyrosine phosphatase, receptor type, B NS NS NEGATIVE NS 
PTPRR protein tyrosine phosphatase, receptor type, R NEGATIVE NS NS NS 
PTPRV protein tyrosine phosphatase, receptor type, V POSITIVE NS NS NS 
RNGTT RNA guanylyltransferase and 5'-phosphatase NEGATIVE NS NS NS 
SKIP 
skeletal muscle and kidney enriched inositol 
phosphatase NS NS NEGATIVE NS 
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5.6 Figures 
 
 
Figure 5-1 
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Figure 5-1: High-throughput screening data.  Normalized photon flux data for 206 
targeted phosphatases is shown at 45(a) and 245(b) minutes after Salmonella stimulation.  
Data is the average of three replicates.  Dotted blue and dashed red lines show 
significance cut-offs for low (α = 0.1) and high (α = 0.02) stringency targeted error rates, 
respectively.   
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Figure 5-2:  PTPNS1, PPM1L, ALP1, PPM1A and PPM1G modulate Salmonella-
induced NF-κB pathways.  The normalized photon flux data from the primary screen at 
45 minutes and at 245 minutes are plotted on the x- and y- axes, respectively.  
Highlighted points show data from specific screening hits and TLR5 control wells.   
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CHAPTER 6 
Conclusions and Future Directions 
6.1 Salmonella Interactions with Neoplastic Cells 
In this work, Salmonella demonstrated invasion of cancer cells in vitro.  However, 
whether Salmonella are capable of invading host cells in a tumor in vivo remains to be 
proven definitively.  Existing data does seem to indicate, that in a tumor 
microenvironment, the majority individual bacteria remain in the extracellular space [1].    
This may prove to be an advantage, though, when using bacteria to deliver toxins to 
tumors in vivo.  The promoters identified in this work are regulated by a low pH 
environment.  While the intracellular pH in tumors is similar to that of normal cells, the 
extracellular pH in the tumor microenvironment is particularly acidic [2].  Therefore, a 
pH-regulated promoter would be specifically activated by extracellular bacteria in the 
tumor microenvironment, but not by bacteria that had invaded tumor cells.  This does 
pose a problem since the toxin utilized to target the tumor must work on the surface of 
the tumor cells or be internalized readily by tumor cells in the area.  In this interest, Shiga 
toxin is an ideal choice for cargo of a therapeutic bacterial vector.  It can be produced 
readily by bacteria and binds the glycosphingolipid globotriaosylceramide (Gb3) cellular 
surface receptor.  Gb3 levels are relatively low in normal tissues, but noted to be highly 
expressed in multiple cancers [3].   By exploiting tumor -targeting bacteria expressing a 
tumor-specific toxin under the control of a tumor microenvironment-induced promoter, a 
highly specific bacterial-based therapeutic could be developed. 
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Studies have also shown that Salmonella may be forming a biofilm in the tumor 
microenvironment [4].  In recent work, microscopic analysis demonstrates bacterial 
biofilm formation at the site of a tumor in vivo [4].  In addition, deletion of genes known 
to be involved in Salmonella biofilm formation enhanced bacterial uptake into tumor 
cells and immune cells [4].  The authors posited that perhaps bacteria are forming 
biofilms in the tumor microenvironment to resist phagocytosis [4].  This work may 
indicate bacterial biofilm genes are an additional set of tumor microenvironment-induced 
promoters that could also be exploited in bacterial tumor-targeting studies.   
Finally, it would be worthwhile to further characterize the regulation of the Salmonella 
genes uncovered in this screen.  For instance, other stimuli bacteria encounter during 
transit through the acidic environments of the stomach and intestines may also induce 
activation of the identified promoters.  Other conditions bacteria may respond to during a 
typical infection include oxygen concentration, osmolarity and acetate concentration , all 
conditions that may also be relevant to growth in the tumor microenvironment [5].    
6.2 How Neoplastic Cells Respond to Salmonella 
Bacterial adaptation to the tumor microenvironment addresses only half of the 
Salmonella-host interaction.  Also at play are the host cells comprising a tumor likely 
respond to the presence of a foreign organism by activating proinflammatory signaling.  
In this work, I demonstrate the response of HCT116 colon carcinoma cells to Salmonella.  
HCT116 cells respond predominantly to bacterial flagellin with a robust activation of NF-
κB signaling.  Interestingly, the dynamics and amplitude of Salmonella-induced NF-κB 
signaling differ from that of TNFα-induced signaling.  Salmonella stimulation of 
HCT116 cells induced less degradation of IκBα, but more and sustained NF-κB 
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transcriptional activation compared to TNFα stimulation.  Perhaps Salmonella and TNFα 
are activating different downstream transcriptional programs of NF-κB.  Microarray 
analysis of Salmonella-treated versus TNFα-treated cells would provide a way to 
interrogate the differences in downstream gene activation.   
To identify novel kinases and phosphatases involved in detection of Salmonella and 
activation of proinflammatory signaling, an siRNA high-throughput screen was utilized.  
One striking observation from the screening data is that most kinases and phosphatases 
have some effect on NF-κB signaling.  This observation serves to highlight the vast 
amount of interconnectivity between intracellular signaling pathways and must be 
considered when analyzing screen data and selecting candidates for follow-up.  Another 
potential caveat of this high-throughput screen was the use of siRNA for target 
knockdown, a known ligand of TLR3 [6].  While normalizing to negative control, non-
targeting siRNA should account for this effect, TLR3 is also known to activate NF-κB 
signaling, and therefore its potential effect should be acknowledged when choosing 
candidate hits for further study.  Additionally, TLR5-positive, TLR3-negative cell lines 
may serve as a useful tool for follow-up studies.   
In the high-throughput screen, two of the most significant hits at both phases of the 
pathway tested (degradation and resynthesis) were MAP kinase kinases.  Intriguingly, 
IKK has a similar role to MAP kinase kinases in its signal transduction pathway in that its 
activity is one kinase removed from proteins thought to act at the intracellular domain of 
the activated cell surface receptor.  It is tempting, therefore, to consider a model where all 
pathways downstream of an activated TLR are interconnected and interdependent.  
Perhaps proper progression of all signaling pathways downstream of a receptor is 
162 
 
required for appropriate signal transduction in any singular pathway.  For instance, 
blocking the activation of MAP2K2 or MAP2K3 may reprogram all downstream and 
parallel intracellular signaling pathways, thus preventing IKK activation as well.  This 
indicates future studies of intracellular signaling should embrace a global view of cellular 
pathways to fully understand the role of specific proteins. 
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